<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="pmc-domain-id">1559</journal-id><journal-id journal-id-type="pmc-domain">viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12197743</article-id><article-id pub-id-type="pmcid-ver">PMC12197743.1</article-id><article-id pub-id-type="pmcaid">12197743</article-id><article-id pub-id-type="pmcaiid">12197743</article-id><article-id pub-id-type="pmid">40573344</article-id><article-id pub-id-type="doi">10.3390/v17060753</article-id><article-id pub-id-type="publisher-id">viruses-17-00753</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Mpox 2022 to 2025 Update: A Comprehensive Review on Its Complications, Transmission, Diagnosis, and Treatment</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1645-9997</contrib-id><name name-style="western"><surname>Yadav</surname><given-names initials="R">Rajesh</given-names></name><xref rid="af1-viruses-17-00753" ref-type="aff">1</xref><xref rid="fn1-viruses-17-00753" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1506-7836</contrib-id><name name-style="western"><surname>Chaudhary</surname><given-names initials="AA">Anis Ahmad</given-names></name><xref rid="af2-viruses-17-00753" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Srivastava</surname><given-names initials="U">Ujjwal</given-names></name><xref rid="af1-viruses-17-00753" ref-type="aff">1</xref><xref rid="fn1-viruses-17-00753" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8140-2033</contrib-id><name name-style="western"><surname>Gupta</surname><given-names initials="S">Saurabh</given-names></name><xref rid="af3-viruses-17-00753" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rustagi</surname><given-names initials="S">Sarvesh</given-names></name><xref rid="af4-viruses-17-00753" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4464-5989</contrib-id><name name-style="western"><surname>Rudayni</surname><given-names initials="HA">Hassan Ahmed</given-names></name><xref rid="af2-viruses-17-00753" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kashyap</surname><given-names initials="VK">Vivek Kumar</given-names></name><xref rid="af5-viruses-17-00753" ref-type="aff">5</xref><xref rid="af6-viruses-17-00753" ref-type="aff">6</xref><xref rid="c1-viruses-17-00753" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6296-0291</contrib-id><name name-style="western"><surname>Kumar</surname><given-names initials="S">Sanjay</given-names></name><xref rid="af7-viruses-17-00753" ref-type="aff">7</xref><xref rid="af8-viruses-17-00753" ref-type="aff">8</xref><xref rid="af9-viruses-17-00753" ref-type="aff">9</xref><xref rid="c1-viruses-17-00753" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Fantini</surname><given-names initials="J">Jacques</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Gallinella</surname><given-names initials="G">Giorgio</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-17-00753"><label>1</label>Sharda School of Allied Health Sciences, Sharda University, Greater Noida 201310, India; <email>rajesh.yadav1@sharda.ac.in</email> (R.Y.); </aff><aff id="af2-viruses-17-00753"><label>2</label>Department of Biology, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 11623, Saudi Arabia</aff><aff id="af3-viruses-17-00753"><label>3</label>Department of Biotechnology, GLA University, Mathura 281406, India</aff><aff id="af4-viruses-17-00753"><label>4</label>Department of Food Technology, School of Agriculture, Maya Devi University, Dehradun 248011, India</aff><aff id="af5-viruses-17-00753"><label>5</label>South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA</aff><aff id="af6-viruses-17-00753"><label>6</label>Division of Cancer Immunology and Microbiology, Medicine and Oncology Integrated Service Unit, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA</aff><aff id="af7-viruses-17-00753"><label>7</label>Biological and Bio-Computational Laboratory, Sharda School of Bio-Sciences and Technology, Sharda University, Greater Noida 201310, India</aff><aff id="af8-viruses-17-00753"><label>8</label>DST-FIST Facility, Sharda University, Greater Noida 201310, India</aff><aff id="af9-viruses-17-00753"><label>9</label>Centre of Excellence in Artificial Intelligence in Medicine, Imaging and Forensic, Sharda University, Greater Noida 201310, India</aff><author-notes><corresp id="c1-viruses-17-00753"><label>*</label>Correspondence: <email>vivek.kashyap@utrgv.edu</email> (V.K.K.); <email>sanjay.kumar7@sharda.ac.in</email> (S.K.)</corresp><fn id="fn1-viruses-17-00753"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>25</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>17</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">491454</issue-id><elocation-id>753</elocation-id><history><date date-type="received"><day>02</day><month>3</month><year>2025</year></date><date date-type="rev-recd"><day>06</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>21</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>25</day><month>05</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>26</day><month>06</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-28 09:25:13.673"><day>28</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="viruses-17-00753.pdf"/><abstract><p>Monkeypox virus (Mpox virus) is a zoonotic orthopoxvirus that has gained increased global attention due to recent outbreaks. The current review reports the latest update of Mpox cases from 25 February 2022 to 29 April 2025. It also evaluates the possible major complications in human life caused by Mpox. In early 2022, more than 40 countries reported Mpox outbreaks. As of 12 June 2024, the global case count for the 2022&#8211;2023 Mpox outbreak was 97,281 confirmed cases, in 118 countries. The World Health Organization (WHO) declared the Mpox virus, a zoonotic disease, a public health emergency of international concern (PHEIC) on 14 August 2024. Mpox symptoms include fever, headache, muscle pain, and face-to-body rashes. The review also highlights Mpox virus replication, genomics, pathology, transmission, diagnosis, and antiviral therapies. The 2022 outbreak is also discussed in detail. The coinfection of HIV in patients infected with Mpox is also discussed. The evolving Mpox epidemiology has raised concerns about the disease&#8217;s increasing spread in non-endemic countries, emphasizing the urgent need for control and prevention. The discussion on preventive measures, including vaccination, suggests that cross-protection against Mpox may be possible using orthopoxvirus-specific antibodies. Although there are no specific antiviral drugs available, certain drugs, such as tecovirimat, cidofovir, and ribavirin, are worth considering.</p></abstract><kwd-group><kwd>monkeypox (Mpox)</kwd><kwd>pathology</kwd><kwd>complication</kwd><kwd>virus replication</kwd><kwd>epidemiology</kwd><kwd>diagnosis and treatment of Mpox</kwd></kwd-group><funding-group><award-group><funding-source>Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University (IMSIU)</funding-source><award-id>IMSUI-DDRSP2501</award-id></award-group><funding-statement>This work was supported and funded by the Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University (IMSIU) (grant number IMSUI-DDRSP2501).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-17-00753"><title>1. Introduction</title><p>Monkeypox is a viral disease caused by the Mpox virus. According to the latest report (29 April 2025) of the World Health Organization (WHO) globally, 137,892 confirmed cases of Mpox have been reported from 1 January 2022 to 31 March 2025. Out of these, 317 deaths were confirmed across 132 countries [<xref rid="B1-viruses-17-00753" ref-type="bibr">1</xref>]. Mpox virus is an enveloped double-stranded DNA with around 200 kb of nucleotides, which is brick-shaped and has a tubule-like structure on its surface [<xref rid="B2-viruses-17-00753" ref-type="bibr">2</xref>]. Additionally, it has a dumbbell-shaped core structure that measures up to 200 to 250 nm. This virus belongs to the genus Orthopoxvirus (OPXV) and the family of <italic toggle="yes">poxviridae</italic> [<xref rid="B3-viruses-17-00753" ref-type="bibr">3</xref>]. Mpox resembles smallpox, and the disease is spread via zoonosis. There are two clades of Mpox: clade I (formerly the Central African clade or the Congo Basin clade) and Clade II (formerly the West African clade). Both have a sequence similarity of about 95%. The fatality rate of clade I is three times higher than that of clade II [<xref rid="B4-viruses-17-00753" ref-type="bibr">4</xref>]. Mpox has a linear DNA genome that contains around 190 non-overlapping open reading frames (ORFs) [<xref rid="B5-viruses-17-00753" ref-type="bibr">5</xref>]. Mpox genomes contain a highly conserved central region, while the terminal region is highly variable, having inverted terminal repeats (ITR) [<xref rid="B6-viruses-17-00753" ref-type="bibr">6</xref>]. All Mpox viruses have four ORFs in the ITR region [<xref rid="B5-viruses-17-00753" ref-type="bibr">5</xref>,<xref rid="B7-viruses-17-00753" ref-type="bibr">7</xref>]. The gene loss at the terminal region acts as a driving force for the evolution of the new Mpox. The ultrastructural analysis study in 2022 revealed that virus replication occurs in the mini-nucleus, which is reorganized by endoplasmic reticulum cisternae in the host cell. The early mRNA and late mRNA form in the mini nucleus, which consecutively form the early protein and the late protein. As a result, an intracellular mature virus (IMV) is released in the cytoplasm and comes outside of the cell by exocytosis to form an enveloped extracellular virus or extracellular mature virus (EMV), which is ready to infect another host cell [<xref rid="B8-viruses-17-00753" ref-type="bibr">8</xref>] (<xref rid="viruses-17-00753-f001" ref-type="fig">Figure 1</xref>). Mpox is not considered a sexually transmitted disease, although the Mpox virus DNA was detected in semen and seminal fluid samples in Italy and Germany in the 2022 global outbreak. Despite various studies on the Mpox virus, the anal or vaginal route can be considered a mucosal membrane route [<xref rid="B9-viruses-17-00753" ref-type="bibr">9</xref>]. Virus mutation and the re-emergence of pathogens with unusual transmission routes may enhance infection and increase the possibility of an epidemic.</p><p>Since 2022, two major Mpox outbreaks have prompted the World Health Organization (WHO) to declare public health emergencies of international concern, first in July 2022 and again in August 2024. The initial global spread, attributed to a clade 2b strain, resulted in roughly 100,000 cases and 200 fatalities [<xref rid="B10-viruses-17-00753" ref-type="bibr">10</xref>]. Subsequently, a new clade, 1b, emerged, leading to a second surge. As of December 2024, this recent outbreak has seen over 55,000 reported or suspected cases and approximately 1000 deaths, primarily in the Democratic Republic of Congo and neighboring nations such as Burundi, Rwanda, Uganda, and Angola [<xref rid="B11-viruses-17-00753" ref-type="bibr">11</xref>]. Isolated cases of clade 1b have also been documented in countries including the UK, Sweden, Germany, Belgium, France, the USA, Canada, and Thailand. The details of the outbreaks of 2024 and 2022 are as follows.</p><sec id="sec1dot1-viruses-17-00753"><title>1.1. The 2024 Outbreak</title><p>The Mpox clade 1b variant, initially detected in the Sud Kivu area of the Democratic Republic of Congo (DRC), has emerged as a major public health threat due to its increased ability to spread between people [<xref rid="B12-viruses-17-00753" ref-type="bibr">12</xref>]. Genetic investigation of clade 1b has uncovered numerous mutations of Mpox. The genetic makeup of clade 1b shows several mutations in genes related to the enzyme apolipoprotein B mRNA editing catalytic polypeptide-like 3 (APOBEC3) cytosine deaminase. This enzyme&#8217;s involvement is often indicative of sustained human-to-human transmission [<xref rid="B13-viruses-17-00753" ref-type="bibr">13</xref>]. These genetic alterations distinguish clade 1b from the traditionally circulating clade I variant, enabling more efficient spread through close physical contact, including sexual contact. </p><p>Genetic changes, particularly those linked to APOBEC3, are thought to contribute to clade 1b&#8217;s enhanced transmissibility.</p><p>Since its initial identification, this variant has expanded its reach within the DRC to other provinces and has also been reported in neighboring nations like Rwanda, Uganda, and Kenya, signifying a considerable geographical expansion of the outbreak [<xref rid="B14-viruses-17-00753" ref-type="bibr">14</xref>,<xref rid="B15-viruses-17-00753" ref-type="bibr">15</xref>].</p><p>The Democratic Republic of Congo was the epicenter and reported 3235 Mpox infections and 19 deaths as of 11 August 2024 [<xref rid="B16-viruses-17-00753" ref-type="bibr">16</xref>]. The emergence of the clade 1b Mpox in neighboring Central and East African countries has raised significant concerns about the potential for a wider regional epidemic. Burundi had recorded 545 Mpox alerts by 17 August 2024, and 142 were confirmed positive for the clade Ib Mpox variant. Rwanda confirmed its initial two Mpox infections on 24 July 2024, prompting the Ministry of Health to declare an outbreak on July 27. By 7 August 2024, Rwanda had reported a total of four confirmed cases of the clade 1b variant of Mpox, with no associated deaths. In Uganda, initially, six suspected cases were identified in June 2024, and out of those six, two were confirmed later. As of 13 August 2024, Kenya has identified 14 suspected cases, with one confirmed positive for clade Ib Mpox. To date, no deaths have been reported.</p><p>In August 2024, the clade 1b strain&#8217;s spread beyond Africa was confirmed for the first time [<xref rid="B15-viruses-17-00753" ref-type="bibr">15</xref>]. The virus has also extended its reach to countries in East Africa, Europe, and Asia, underscoring its capacity for worldwide spread [<xref rid="B16-viruses-17-00753" ref-type="bibr">16</xref>]. Sweden reported a case involving a traveler returning from an affected region, demonstrating the pivotal role of international travel in spreading infectious diseases globally [<xref rid="B17-viruses-17-00753" ref-type="bibr">17</xref>]. This event prompted urgent calls for governments to enhance border checks, implement targeted surveillance, and foster international collaboration to control cross-border disease transmission. On 22 August 2024, Thailand reported its initial Mpox case of a European man with a recent travel history to Africa [<xref rid="B18-viruses-17-00753" ref-type="bibr">18</xref>]. Likewise, India&#8217;s identification of its first imported clade 1b Mpox case in Kerala highlights the potential for international travel to contribute to the dissemination of this variant.</p><p>From November 2024 to 12 February 2025, four cases of clade Ib were detected. In the United States, the first confirmed case of clade Ib Mpox occurred in California in November 2024, following travel to an affected region. A second case was identified in Georgia on 14 January 2025, involving a traveler from a country with ongoing Mpox transmission. Subsequent cases were reported in New Hampshire on 7 February 2025 and in New York on 12 February 2025. These four cases represent independent events, with no epidemiological links established and no evidence of further transmission [<xref rid="B19-viruses-17-00753" ref-type="bibr">19</xref>]. The 2024 outbreak emphasized the importance of aligning travel health policies with robust outbreak management strategies to minimize risks from rapidly spreading pathogens [<xref rid="B15-viruses-17-00753" ref-type="bibr">15</xref>].</p><p>A significant public health crisis unfolded between 2022 and 31 December 2024, with global records documenting over 118,777 Mpox infections [<xref rid="B20-viruses-17-00753" ref-type="bibr">20</xref>]. Between 2022 and 2024, the different regions of the Americas documented 67,220 confirmed Mpox cases, resulting in 151 deaths across 31 countries and territories [<xref rid="B20-viruses-17-00753" ref-type="bibr">20</xref>]. The majority of these cases occurred in 2022 (57,616, representing 85.7% of the total), followed by a substantial decline in 2023 (4056 cases, 6%). A minor increase was observed in 2024, with 5548 cases (8.3%) [<xref rid="B20-viruses-17-00753" ref-type="bibr">20</xref>]. The World Health Organization (WHO) has determined that the highly contagious clade 1b strain is the primary driver of this outbreak, characterized by severe symptoms and increased mortality [<xref rid="B21-viruses-17-00753" ref-type="bibr">21</xref>]. The most affected areas that reported a large number of infections were East, Central, West, and Southern Africa, specifically, Burundi, Kenya, Rwanda, Uganda, the Central African Republic (CAR), Ivory Coast, and South Africa [<xref rid="B22-viruses-17-00753" ref-type="bibr">22</xref>]. The swift dissemination of the virus in these areas underscores the critical need for collaborative containment efforts and enhanced healthcare systems to effectively address such epidemics.</p></sec><sec id="sec1dot2-viruses-17-00753"><title>1.2. The 2022 Outbreak</title><p>Before 2022, Mpox cases were documented within the African continent. The first case of the 2022 outbreak of the Mpox outside the African continent was recorded on 6 May 2022 in the United Kingdom [<xref rid="B23-viruses-17-00753" ref-type="bibr">23</xref>]. A total of 366 Mpox cases were confirmed in the United Kingdom (UK) until 10 June 2022 [<xref rid="B24-viruses-17-00753" ref-type="bibr">24</xref>,<xref rid="B25-viruses-17-00753" ref-type="bibr">25</xref>]. On 18 May 2022, Portugal reported 14 Mpox infections, Spain reported seven, and Canada reported 13. The first Mpox cases in Belgium, Sweden, and Italy were confirmed on 19 May 2022. France, Germany, Australia, and the Netherlands each reported their initial Mpox cases on 20 May 2022. Switzerland and Israel each confirmed their initial Mpox cases on May 21. By 24 May 2022, 19 countries had reported cases of Mpox. Among these, the United Arab Emirates identified its first case in late May, involving a 29-year-old female traveler from West Africa. Slovenia also confirmed its initial infection. Denmark&#8217;s first case was linked to an individual returning from the Canary Islands. In Canada, Quebec reported fifteen confirmed cases on 24 May, the same day the Czech Republic confirmed its first case [<xref rid="B24-viruses-17-00753" ref-type="bibr">24</xref>]. The study published in the New England Journal on 21 July 2022 reported a total of 528 Mpox infections between 27 April and 24 June 2022, at 43 sites within 16 countries [<xref rid="B26-viruses-17-00753" ref-type="bibr">26</xref>].</p><p>By 27 May 2022, Portugal had confirmed 96 Mpox cases, and the information regarding demographics, clinical presentation, and exposure was collected from all 96 cases via face-to-face and telephone interviews using standardized case investigation forms. A subset of 27 confirmed cases underwent more detailed investigation, and their sociodemographic and clinical characteristics, along with available laboratory and epidemiological findings, are summarized in a previous study published in Eurosurveillance in June 2022 [<xref rid="B27-viruses-17-00753" ref-type="bibr">27</xref>]. The majority of cases (25 cases) of the 2022 Portugal outbreak resided in the Lisbon and Tagus Valley (LVT) region, with single cases in the North and Algarve regions. All cases were male, ages ranging from 22 to 51 years (majority 30&#8211;39). Considering exposures within the 21 days preceding symptom onset, few (1/10) reported contact with individuals exhibiting similar symptoms, and some had a history of international travel (4/27).</p><p>Most cases were identified as men who have sex with men (MSM) (18/19), while one reported sex with only women. During the 21 days before symptom onset, most cases with available data (14/16) reported multiple sexual partners. Six cases reported attending a sauna in the LVT region, one frequented a UK sauna, and four reported international travel&#8212;three reported contacts with animals (two with cats and one with pigs). Common symptoms included exanthema (fourteen), inguinal lymphadenopathy (fourteen), fever (thirteen), and genital ulcers (six). Fourteen cases were HIV-positive. Three cases required hospitalization, two of whom were later discharged. No deaths were reported by 27 May 2022. One middle-aged case reported prior smallpox vaccination [<xref rid="B27-viruses-17-00753" ref-type="bibr">27</xref>].</p><p>In May 2022, the World Health Organization (WHO) declared a global health emergency for a previous Mpox outbreak caused by clade IIb of the virus. Almost 48 cases of Mpox were reported from different regions of Latin America, such as Brazil, Argentina, Peru, Venezuela, Mexico, Colombia, and Chile, by 28 June 2022 [<xref rid="B28-viruses-17-00753" ref-type="bibr">28</xref>]. In July 2022, the multi-country Mpox outbreak was declared a Public Health Emergency of International Concern (PHEIC) due to its rapid spread through sexual contact in regions previously unaffected by the virus. This declaration was lifted in May 2023 following a sustained global decline in cases. The outbreak had infected 87,000 people and resulted in 140 deaths. The WHO attributed the successful containment to a combination of vaccination and public health information campaigns [<xref rid="B29-viruses-17-00753" ref-type="bibr">29</xref>]. Most of these countries have set up their epidemiological centers for the identification of these viruses. According to the Centers for Disease Control and Prevention, as of 7 February 2024, the maximum number of reported cases in the USA is 31,894, followed by Brazil (10,967), Spain (7752), and France (4171).</p><p>The geographical distribution of the Mpox in countries affected in Africa is illustrated in <xref rid="viruses-17-00753-f002" ref-type="fig">Figure 2</xref>a, while the recent trends of Mpox cases in Africa are shown in <xref rid="viruses-17-00753-f002" ref-type="fig">Figure 2</xref>b.</p></sec></sec><sec id="sec2-viruses-17-00753"><title>2. Host Reservoirs and Transmission</title><p>Mpox is a zoonotic disease; Central African rodents and primates are the natural hosts of Mpox. The Mpox virus is primarily transmitted from animals to humans through close contact, such as bites, scratches, or exposure to the animal&#8217;s rash, as well as through exposure to their bodily fluids or consumption of improperly cooked meat [<xref rid="B30-viruses-17-00753" ref-type="bibr">30</xref>]. Transmission can also occur via contaminated materials (fomites) like bedding or clothing. Historically, human-to-human transmission has been less frequent.</p><p>A 2018 case study reported that a man traveling from Nigeria to the UK on September 6th presented with a maculopapular rash, fever, and lymphadenopathy and was subsequently diagnosed with Mpox. One of the three attending healthcare workers developed symptoms, was isolated, and had 134 contacts traced and monitored. Four of these contacts later became ill. This incident demonstrates human-to-human transmission of Mpox from a traveler returning from Nigeria to healthcare staff [<xref rid="B31-viruses-17-00753" ref-type="bibr">31</xref>].</p><p>Historically, Mpox infection was primarily linked to animal contact or travel to endemic regions. However, the transmission pattern shifted in the 2022 outbreak, with most cases now attributed to sexual contact. Over the last two years (2020&#8211;22), predominantly gay and bisexual men have been affected [<xref rid="B32-viruses-17-00753" ref-type="bibr">32</xref>]. The study reveals that the risk of public transmission was very low because Mpox virus transmission from human to human requires close contact. Human-to-human transmission of the Mpox virus occurred through direct contact through blood transfusion, respiratory droplet infection, sharing of foods, clothes, and bedding, and sexual activity, especially with male-to-male sex [<xref rid="B33-viruses-17-00753" ref-type="bibr">33</xref>].</p><p>The Mpox virus may be transmitted from the mother to the fetus during pregnancy, and that type of transmission is called vertical transmission [<xref rid="B34-viruses-17-00753" ref-type="bibr">34</xref>]. The different proposed model admits that during the entry of the Mpox virus through the respiratory epithelium in humans, the Mpox virus enters dendritic cells and macrophages, which then enter lymphatic vessels and the lymphatic system. In the same way, when the Mpox virus infects the skin epidermis, it first infects fibroblast cells and Langerhans cells, which move in lymphatic vessels and then into the lymphatic system. In this way, it spreads all over the body and infects the liver, which may cause serious liver problems (<xref rid="viruses-17-00753-f003" ref-type="fig">Figure 3</xref>).</p></sec><sec id="sec3-viruses-17-00753"><title>3. Complications Associated with Mpox</title><p>The various complications that have been observed in Mpox-infected persons are the following.</p><sec id="sec3dot1-viruses-17-00753"><title>3.1. Neurological and Psychiatric Complications</title><p>Mpox infections are associated with potential neurological and mental health complications. Research conducted in Nigeria in 2020 indicated that a quarter of hospitalized Mpox patients experienced psychiatric symptoms, such as anxiety, depression, and suicidal ideation [<xref rid="B35-viruses-17-00753" ref-type="bibr">35</xref>]. However, it is difficult to isolate these symptoms from the psychological impact of hospitalization and isolation. Neurological issues, including seizures, confusion, and encephalitis, were observed in Mpox patients during the 2022 outbreak, with reported occurrences of 2.7%, 2.4%, and 2%, respectively [<xref rid="B36-viruses-17-00753" ref-type="bibr">36</xref>]. Furthermore, cerebrospinal fluid (CSF) analysis revealed the presence of Mpox-specific IgM antibodies. Studies indicate that neuropsychiatric symptoms are common in 50% of individuals with Mpox infection. Badenoch and colleagues suggest that symptoms occur in more than half of cases [<xref rid="B36-viruses-17-00753" ref-type="bibr">36</xref>]. These symptoms may arise from the infection itself or the experience of quarantine [<xref rid="B37-viruses-17-00753" ref-type="bibr">37</xref>]. Additionally, research conducted in Iraq has revealed widespread anxiety among the general population concerning the ongoing Mpox outbreak [<xref rid="B38-viruses-17-00753" ref-type="bibr">38</xref>]. This research sought to evaluate public awareness, perceptions, and anxiety related to the multi-country Mpox outbreak within the Kurdistan region of Iraq. A digital survey utilizing a convenience sampling approach was conducted from 27 to 30 July 2022. The study included 510 participants. Overall, the population demonstrated a moderate understanding of Mpox, held a neutral attitude toward it, and experienced a moderate level of anxiety. Statistical analysis revealed that demographic factors, including gender, religion, education level, and place of residence, significantly impacted awareness and anxiety levels. Gender and the residential area also played a significant role in shaping attitudes toward Mpox [<xref rid="B38-viruses-17-00753" ref-type="bibr">38</xref>].</p></sec><sec id="sec3dot2-viruses-17-00753"><title>3.2. Dermatological Complications</title><p>A common characteristic of Mpox infection is the appearance of skin lesions, particularly in the anogenital region. Skin lesions present as a rash that progresses through distinct stages: initially flat (macular), then raised (popular), and subsequently fluid-filled (vesicular). These lesions typically resolve with crusting within three weeks [<xref rid="B39-viruses-17-00753" ref-type="bibr">39</xref>]. A characteristic Mpox rash begins with small, flat (macules) or raised (papules) lesions, typically 0.5 to 1 cm in diameter. These lesions progress over two to three weeks, evolving into fluid-filled vesicles and pus-filled pustules, often with a central depression (umbilication), and eventually form crusts. The vesicles and pustules themselves are generally spherical, ranging from 0.5 to 2 cm in diameter, and are notable for their firm texture, deep skin involvement, and well-defined edges [<xref rid="B40-viruses-17-00753" ref-type="bibr">40</xref>].</p><p>A hallmark of Mpox is a unique rash characterized by painful or itchy maculopapular lesions that progress into a vesiculopustular eruption [<xref rid="B41-viruses-17-00753" ref-type="bibr">41</xref>]. Typically, the rash emerges within one to three days following the onset of initial symptoms. However, variations exist, with some individuals experiencing the rash more than three days after fever onset or concurrently with the fever. Lesions commonly manifest on the face, trunk, extremities, genital region, scalp, palms, and soles. The rash often begins on the face and then spreads outward (centrifugally) to the limbs, palms, soles, and mucous membranes of the mouth, eyes, and genitals. A higher concentration of lesions is generally observed on the face and limbs [<xref rid="B42-viruses-17-00753" ref-type="bibr">42</xref>]. In some cases, oral lesions, known as enanthems, may precede the appearance of the skin rash. A comprehensive review of available research indicates that sore throat is the most frequently reported oral symptom of Mpox, while ulceration is the most common oral or peri-oral sign [<xref rid="B43-viruses-17-00753" ref-type="bibr">43</xref>].</p><p>In one study of 54 patients, all presented with skin lesions, with a significant majority (94%) exhibiting anogenital involvement [<xref rid="B44-viruses-17-00753" ref-type="bibr">44</xref>]. A large portion of these patients (89%) reported lesions at multiple anatomical sites, and a smaller percentage (7%) had lesions in the oropharyngeal area. Additionally, a substantial number of patients experienced fatigue (67%) and fever (57%), while a minority (18%) showed no initial symptoms. In some cases, genital ulcers were observed to be painless, accompanied by bilateral inguinal lymphadenopathy, resembling the presentation of primary syphilis [<xref rid="B45-viruses-17-00753" ref-type="bibr">45</xref>].</p><p>A separate international study, tracking 528 Mpox infections in 2022, also identified anogenital lesions as a prevalent symptom. This study found that 73% of patients had anogenital lesions, and 41% presented with mucosal lesions. A rash was observed in 95% of patients, with other frequently reported symptoms including fever (62%), lymphadenopathy (56%), lethargy (41%), muscle aches (31%), and headaches (27% [<xref rid="B26-viruses-17-00753" ref-type="bibr">26</xref>]). Due to the varied and evolving clinical presentation of Mpox, especially as seen in the 2022 outbreak, medical professionals, particularly dermatologists, are advised to exercise a high degree of vigilance when evaluating patients with suspected Mpox infection.</p><p>The other study, conducted in 101 patients from thirteen countries, shows that 54% of cases have been found with skin lesions. During the initial five days of infection, papules (36%), vesicles (17%), and pustules (20%) were the most frequently observed skin lesions. From days 6&#8211;10, pustules became the dominant lesion (36%), followed by erosions/ulcers (27%) and crusts/scabs (24%). After day 11, crusts/scabs were the primary skin manifestation [<xref rid="B46-viruses-17-00753" ref-type="bibr">46</xref>].</p><p>While monkeypox treatment remains largely symptomatic due to the lack of specific antiviral medications, a novel therapeutic approach combining antimicrobial photodynamic therapy (aPDT) and photobiomodulation therapy (PBMT) successfully treated a large facial cutaneous lesion, highlighting its potential as a promising intervention [<xref rid="B47-viruses-17-00753" ref-type="bibr">47</xref>].</p></sec><sec id="sec3dot3-viruses-17-00753"><title>3.3. Complications Related to the Coinfection of Mpox Virus and HIV</title><p>The COVID-19 pandemic, which began in 2020, demonstrated the rapid emergence of viral diseases and the potential for global spread, highlighting the ongoing threat of Mpox. Mpox may be more lethal for immunocompromised people, such as those infected with the human immunodeficiency virus (HIV). The coinfection of Mpox virus and HIV was first identified and diagnosed in Latin America [<xref rid="B48-viruses-17-00753" ref-type="bibr">48</xref>]. In 2022, the recent coinfection of Mpox and acute HIV was also confirmed in a 24-year-old male with outstretched papules throughout the trunk, face, and genital area [<xref rid="B49-viruses-17-00753" ref-type="bibr">49</xref>]. A 2023 review in <italic toggle="yes">Vaccine</italic> reported 6345 confirmed Mpox cases across 53 studies, with a 40.32% HIV co-infection rate [<xref rid="B50-viruses-17-00753" ref-type="bibr">50</xref>]. According to WHO, 51% (13,769/26,992) of confirmed cases of Mpox have HIV [<xref rid="B51-viruses-17-00753" ref-type="bibr">51</xref>]. The outbreak of Mpox in multiple countries was reported during 2022&#8211;24. According to the WHO report, the maximum number of confirmed cases came from the European region (86%), followed by America (11%), the African region (2%), and the Eastern Mediterranean region (1%) [<xref rid="B52-viruses-17-00753" ref-type="bibr">52</xref>]. Co-infection with HIV increases the chance of infection in an uninfected person by enhancing the concentration of HIV on genital organs (lesions) and genital secretions or by increasing both factors [<xref rid="B53-viruses-17-00753" ref-type="bibr">53</xref>,<xref rid="B54-viruses-17-00753" ref-type="bibr">54</xref>]. Individuals living with HIV, especially those with compromised immune systems characterized by low CD4 cell counts (&lt;500 cells per mm<sup>3</sup>), demonstrate an increased vulnerability to severe Mpox complications and mortality compared to those without HIV. The immunodeficiency resulting from advanced HIV infection elevates the susceptibility to severe Mpox manifestations, which can include necrotizing skin lesions, pulmonary involvement, secondary infections, and sepsis [<xref rid="B55-viruses-17-00753" ref-type="bibr">55</xref>].</p><p>This study analysed 382 Mpox cases, comprising 367 cisgender males, four cisgender females, and ten transgender females. The median age of the participants was 35 years, with an interquartile range (IQR) of 30 to 43 years. At the time of Mpox diagnosis, 349 individuals (91%) were known to be living with HIV. Among those with HIV, 228 (65%) were adhering to antiretroviral therapy (ART). Concurrent opportunistic infections were observed in 32 participants (8%). The median CD4 cell count was 211 cells/mm<sup>3</sup> (IQR 117&#8211;291). Specifically, 85 individuals (22%) had CD4 counts below 100 cells/mm<sup>3</sup>, and 94 individuals (25%) had counts between 100 and 200 cells/mm<sup>3</sup>. An undetectable viral load was present in 193 participants (51%) [<xref rid="B55-viruses-17-00753" ref-type="bibr">55</xref>].</p><p>Severe Mpox complications were significantly more prevalent in individuals with CD4 counts below 100 cells/mm<sup>3</sup> compared to those with counts exceeding 300 cells/mm<sup>3</sup>. These complications included the following: necrotizing skin lesions (54% vs. 7%), pulmonary involvement, sometimes with nodules (29% vs. 0%), and secondary infections and sepsis (44% vs. 9%).</p><p>Hospitalization was required for 107 participants (28%), with 27 (25%) of those hospitalized resulting in death. All fatalities occurred in individuals with CD4 counts below 200 cells/mm<sup>3</sup>. Within this group, mortality was higher among those with elevated HIV viral loads. Immune reconstitution inflammatory syndrome (IRIS) related to Mpox was suspected in 21 of the 85 individuals (25%) who initiated or restarted ART, with 12 (57%) of these cases resulting in death. Tecovirimat was administered to 62 participants (16%), while cidofovir or brincidofovir was used in seven participants (2%). Tecovirimat resistance was confirmed in three cases.</p></sec><sec id="sec3dot4-viruses-17-00753"><title>3.4. Complications Associated with Heart (Myocarditis)</title><p>Myocarditis, pericarditis, and myopericarditis have been rarely documented in Mpox infection. Two immunocompetent, unvaccinated adults in the U.S. developed monkeypox-related myocarditis. They were hospitalized and presented with cardiac symptoms (Chest pain) and elevated biomarkers. Oral tecovirimat and doxycycline were provided for the treatment of monkeypox, and they were discharged home after recovery without immediate complications. They received no specific treatment for myocarditis, given the rapid resolution of symptoms and normalization of troponin levels [<xref rid="B56-viruses-17-00753" ref-type="bibr">56</xref>].</p><p>In a 2022 study, Thornhill et al. documented two instances of self-limiting myocarditis associated with monkeypox, where patients recovered within seven days without significant complications. One of these patients had a history of HIV with a normal CD4 count [<xref rid="B26-viruses-17-00753" ref-type="bibr">26</xref>].</p><p>A wide range of viruses are known to cause myocarditis, such as Coxsackieviruses and adenoviruses [<xref rid="B57-viruses-17-00753" ref-type="bibr">57</xref>]. Viral myocarditis can cause dilated cardiomyopathy. The most frequently observed pathological process involves lymphocytic myocarditis with myocyte necrosis, typically developing 10 to 14 days after the viral infection. The occurrence of myocardial involvement in orthopoxvirus infections was initially documented following smallpox vaccination in young military recruits, using live vaccinia-based vaccines [<xref rid="B58-viruses-17-00753" ref-type="bibr">58</xref>]. The precise pathophysiological pathways leading to orthopox-induced myocarditis remain to be determined. Heart failure, arrhythmias, and other cardiovascular-related problems may also be possible in Mpox infection [<xref rid="B59-viruses-17-00753" ref-type="bibr">59</xref>].</p></sec><sec id="sec3dot5-viruses-17-00753"><title>3.5. Hypotension Sepsis Complication</title><p>In severe cases, significant fluid loss due to fever, rash, and capillary permeability can occur. The associated systemic inflammatory response may also contribute to hypotension. These factors combine to reduce renal perfusion, potentially leading to acute kidney injury. Vigilant monitoring of urine output and blood chemistry is essential for early detection and to guide the necessity of intravenous fluid replacement.</p><p>While infrequent, secondary bacterial infections leading to sepsis have been documented in Mpox-infected patients with <italic toggle="yes">Streptococcus pyogenes</italic> [<xref rid="B60-viruses-17-00753" ref-type="bibr">60</xref>]. Prompt identification of sepsis, utilizing standard diagnostic criteria, is essential. Treatment should adhere to established sepsis management protocols, including initiating broad-spectrum empirical antibiotics within one hour of diagnosis, rapid intravenous fluid resuscitation with ongoing response evaluation, vasoactive medication administration, and appropriate respiratory support [<xref rid="B61-viruses-17-00753" ref-type="bibr">61</xref>].</p></sec><sec id="sec3dot6-viruses-17-00753"><title>3.6. Ocular Complication</title><p>Ocular symptoms are uncommon but can cause corneal scarring and vision loss [<xref rid="B3-viruses-17-00753" ref-type="bibr">3</xref>]. Manifestations, potentially from self-inoculation, include conjunctivitis, blepharitis, and other ocular inflammations. The 2022 Mpox outbreak showed a significantly lower ocular involvement rate of approximately 1%, compared to 9&#8211;23% in prior outbreaks [<xref rid="B62-viruses-17-00753" ref-type="bibr">62</xref>]. Mpox can present with a variety of ocular symptoms, including redness, frontal headaches, rashes around the eyes, tearing, discharge, and subconjunctival nodules. Less commonly, it may lead to more severe complications like keratitis, corneal ulcers, opacification, perforation, and vision loss. In the 2022 outbreak, these ocular symptoms have been observed less often and potentially with reduced severity. Though potential underreporting exists, observational studies suggest an ocular involvement rate of approximately 1%, significantly lower than the 9&#8211;23% incidence reported in previous outbreaks in endemic regions [<xref rid="B62-viruses-17-00753" ref-type="bibr">62</xref>,<xref rid="B63-viruses-17-00753" ref-type="bibr">63</xref>]. Newborns have been reported to experience ocular involvement with Mpox [<xref rid="B64-viruses-17-00753" ref-type="bibr">64</xref>]. Additionally, there are documented cases (53-year-old patient in San Francisco, CA, USA) where ocular symptoms presented independently, without concurrent skin lesions [<xref rid="B65-viruses-17-00753" ref-type="bibr">65</xref>].</p><p>Patients presenting with ocular Mpox symptoms should be referred for ophthalmologic evaluation. A slit-lamp examination and dilated fundoscopy are valuable tools for assessing the involvement of both anterior and posterior eye structures [<xref rid="B66-viruses-17-00753" ref-type="bibr">66</xref>].</p><p>Retinol supplementation is advised. Supportive measures such as eye lubrication and saline compresses may provide relief. In cases of co-infection, ophthalmic antibiotics or antivirals may be necessary [<xref rid="B67-viruses-17-00753" ref-type="bibr">67</xref>]. Patients should be instructed to avoid contact lens use [<xref rid="B68-viruses-17-00753" ref-type="bibr">68</xref>]. Topical trifluridine, under ophthalmological guidance, can be considered for conjunctivitis and is recommended for keratitis management.</p></sec><sec id="sec3dot7-viruses-17-00753"><title>3.7. Fulminant Mpox</title><p>A severe, widespread, and destructive form of Mpox has been observed in individuals with advanced immunosuppression, such as those with CD4 counts below 100 cells/&#181;L, high HIV viral loads, or hepatitis B co-infection. These cases show a resemblance to an AIDS-defining illness. Patients showed extensive, large necrotic skin and mucosal lesions that often merged [<xref rid="B69-viruses-17-00753" ref-type="bibr">69</xref>]. Severe secondary bacterial infections were frequent. Complications included lung nodules, necrotic pulmonary masses, nodular hepatic lesions, respiratory insufficiency, and sepsis [<xref rid="B70-viruses-17-00753" ref-type="bibr">70</xref>]. Immune reconstitution inflammatory syndrome (IRIS) was suspected in a quarter of patients initiating or resuming antiretroviral therapy post-diagnosis [<xref rid="B71-viruses-17-00753" ref-type="bibr">71</xref>]. Mortality was reported in 15% of patients, primarily those with CD4 counts below 200 cells/&#181;L [<xref rid="B70-viruses-17-00753" ref-type="bibr">70</xref>].</p><p>In moderately to severely immunocompromised patients with uncontrolled viral dissemination, optimal immune function should be prioritized. Tecovirimat should be initiated promptly, and consider adding cidofovir or brincidofovir and vaccinia immune globulin. Prolonged treatment may be necessary. Wound care is essential, and fluid management may be required. Specialist consultation should be considered as needed. Close monitoring for complications is vital [<xref rid="B72-viruses-17-00753" ref-type="bibr">72</xref>].</p></sec><sec id="sec3dot8-viruses-17-00753"><title>3.8. Complications Associated with Immune System</title><p>Like COVID-19 infection, Mpox also creates cytokines inside the body [<xref rid="B73-viruses-17-00753" ref-type="bibr">73</xref>]. Cytokines are Th2-mediated, and a large number of interleukins (IL-4, IL5, IL6, and IL10) are released, while TH1-mediated cytokines are released in a lower amount. Therefore, IF&#947; (interferon gamma), IL2, IL12, TNF-&#945;, and IFN-&#945; levels decreased after Mpox infection [<xref rid="B74-viruses-17-00753" ref-type="bibr">74</xref>]. The human Mpox virus causes post-translational modification on the host cell. It downregulates those regulatory factors that increase histone expression while upregulating core histone proteins. The nucleosome formation of viruses depends on host nucleosome modification [<xref rid="B75-viruses-17-00753" ref-type="bibr">75</xref>]. Mpox has a specific mechanism through which it defends itself via the immune reaction of the host. The intracellular protein of Mpox called Viro transducer stops apoptosis in the host cell and stops the host cell from responding against the virus [<xref rid="B33-viruses-17-00753" ref-type="bibr">33</xref>,<xref rid="B76-viruses-17-00753" ref-type="bibr">76</xref>]. In this way, these proteins evade the host&#8217;s immune system to allow for viral replication in the host, as shown in <xref rid="viruses-17-00753-f004" ref-type="fig">Figure 4</xref>. The Mpox virus uses various strategies in the host cell to escape from the host immune defense system. Innate immunity is the first line of defense and is operated by interferons (IFNs) [<xref rid="B77-viruses-17-00753" ref-type="bibr">77</xref>]. Interferons prevent viral replication in host cells using direct or indirect pathways. There are three types of interferons: type 1, type 2, and type 3. IFN&#945;, IFN&#946;, and IFN&#969; are considered type I interferons. Type I interferons create antiviral activity in cells by activating Janus protein tyrosine kinase and signal transducers and activators of the transcription (JAK-STAT) pathway [<xref rid="B78-viruses-17-00753" ref-type="bibr">78</xref>]. Mpox virus evades the immune response of the host in the following way: (a) An in vitro study in 2010 showed that Mpox viral protein B16 inhibits JAK-STAT induced by type I interferon [<xref rid="B79-viruses-17-00753" ref-type="bibr">79</xref>]. (b) Another experiment performed in mice in 2004 found that homologs of D7L block interleukin (IL-18) [<xref rid="B80-viruses-17-00753" ref-type="bibr">80</xref>]. The complement control protein (CCP) of Mpox inhibits the complement activation pathway, which is a key factor for viral defense [<xref rid="B81-viruses-17-00753" ref-type="bibr">81</xref>]. Apart from it, many proteins of Mpox are responsible for evasion, including ankyrin-like protein, viral growth factor, IL-18 binding protein, apoptosis inhibitors, SPI-1, inhibitors of MHC class I molecules, inhibitors of IRF3 NF-kB activation, Inhibitor of IRF3 and IRF7 activation, inhibitors of MHC class II, CC, and CXC chemokine binding proteins.</p></sec></sec><sec id="sec4-viruses-17-00753"><title>4. Diagnosis of Mpox</title><p>PCR (polymerase chain reaction) is a gold standard molecular biology technique that detects the presence of Mpox viral DNA in samples such as blood, skin lesions, or respiratory secretions. PCR is a highly sensitive and specific method used for confirmatory diagnosis. Real-time PCR is the most common diagnostic procedure for the detection of Mpox. In the 2022&#8211;23 outbreak of Mpox, four novel molecular kits were used: The Novaplex MPXV Assay, the STANDARD M10 MPX/OPX, the Real Cycler MONK-UX/MONK-GX v.2, and the RealStar Orthopoxvirus PCR Kit 1.0, with an in-house PCR assay. A comparison study of diagnostic kits shows that sensitivity and specificity were 100% for the Novaplex MPXV Assay and RealStar Orthopoxvirus PCR Kit 1.0. The RealCycler MONK-UX/MONK-GX v.2 and STANDARD M10 MPX/OPX exhibited a slight decrease in the accuracy (97.3%) and diagnostic sensitivity (96.3%) [<xref rid="B82-viruses-17-00753" ref-type="bibr">82</xref>].</p><p>The lab diagnosis of viral infections plays a crucial role in the detection of diseases and their treatment. Cell culture or tissue culture is considered to be the standard method for the isolation and cultivation of viruses, although this method is considered to be time-consuming and has a high risk of contamination [<xref rid="B83-viruses-17-00753" ref-type="bibr">83</xref>]. The other standard methods for the detection of viruses are molecular and non-molecular techniques (immunofluorescence technique and ELISA), electron microscopy-based detection (TEM), radiation-based virus detection (X-ray diffraction technique and CT), nucleic acid amplification methods (NASBA, LAMP, RT-PCR), antigen-antibody complex-mediated detection of viruses (HAI), and CRISPR-CAS system-based detection [<xref rid="B84-viruses-17-00753" ref-type="bibr">84</xref>]. Urine, saliva, semen, and rectal or genital samples can also be taken for investigative purposes, depending on the clinic [<xref rid="B85-viruses-17-00753" ref-type="bibr">85</xref>].</p><p>CRISPR-based detection is also a rising diagnostic method in the field of virology. According to research conducted [<xref rid="B86-viruses-17-00753" ref-type="bibr">86</xref>], a system was designed to detect the Mpox viral DNA using a fluorescence readout. In this study, it was shown that the G-quadruplex oligonucleotide of the target DNA, which was labeled with fluorescein (6-FAM) on the 3-prime end and black hole 1-quencher (BHQ-1) at the 5-prime end, produced a fluorescence signal when it was degraded via the CAS-12a-mediated collateral cleavage. This effect was not shown in the absence of the target DNA because CAS-12a is unable to cleave the labeled G-quadruplex oligonucleotide, and fluorescence quenching happens.</p><p>Pan-orthopoxvirus PCR/ESI-MS is another emerging method in the field of diagnostics; it can perform identification of all members of orthomyxovirus without sequencing by using the T5000 platform [<xref rid="B87-viruses-17-00753" ref-type="bibr">87</xref>]. Here, A PCR method coupled with electrospray ionization mass spectrometry (PCR/ESI-MS) was employed to diagnose Mpox in spiked human samples and aerosol-infected cynomolgus macaque samples.</p><p>Loop-mediated isothermal amplification (LAMP) is another molecular diagnostic technique used in virology, offering a potential alternative to RT-PCR. This technique uses the displacement of the auto-cycling step of DNA synthesis by Bst DNA polymerase, which replicates the gene without the use of a light cycle [<xref rid="B88-viruses-17-00753" ref-type="bibr">88</xref>].</p></sec><sec id="sec5-viruses-17-00753"><title>5. Treatment of Mpox</title><p>The treatment of Mpox primarily focuses on managing symptoms and preventing complications. The symptoms, like fever, pain, and itching, can be treated with acetaminophen or ibuprofen. Antiviral medication such as tecovirimat has been used for some patients with Mpox, particularly those with severe illness or who are at high risk of complications. Other antiviral medications, such as brincidofovir and cidofovir, may be considered in certain situations, but their use is generally limited. Vaccines are also recommended for people at high risk of exposure. To prevent infection with the Mpox virus, avoid close skin contact and contact with contaminated materials (e.g., clothing, bedding). Most people with Mpox experience mild symptoms and recover without specific treatment. Severe cases and complications are more common in individuals with weakened immune systems, children, and pregnant women.</p><sec id="sec5dot1-viruses-17-00753"><title>5.1. Vaccine Strategies Against Mpox</title><p>Almost a thousand cases have been reported from different parts of the world since April 2022, mostly from non-endemic countries; therefore, it has become necessary to understand the possible risk factors associated with this virus. Viral inactivation is a crucial step to prevent the spreading of Mpox; among the methods of viral inactivation, heat inactivation is one of the methods of viral inactivation.</p><p>According to Bat&#233;jat Christophe et al., the Mpox virus was inoculated on two growth media named FCS and VTM and then subjected to heat inactivation at different temperatures over a period. This study showed that Mpox got inactivated in less than 5 min if heated at 70 &#176;C and less than 15 min if heated at 60 &#176;C, and there was no difference between clade I and clade II [<xref rid="B89-viruses-17-00753" ref-type="bibr">89</xref>].</p><p>The United States of America currently has three vaccines against smallpox: JYNNEOS<sup>TM</sup>, also known as IMVAMUNE, ACAM2000<sup>&#174;</sup>, and Aventis Pasteur smallpox vaccine (APSV) [<xref rid="B90-viruses-17-00753" ref-type="bibr">90</xref>]. This vaccine JYNNEOS<sup>TM</sup> has been prepared from the modified Ortho poxvirus vaccinia Ankara-Bavarian Nordic strain and is attenuated in nature and non-replicating.</p><p>In August 2007, the FDA approved ACAM2000<sup>&#174;</sup> for the prevention of smallpox. The ACAM2000<sup>&#174;</sup> vaccine is also a live vaccine but shows some differences with JYNNEOS&#8482;. ACAM2000<sup>&#174;</sup> is a replication-competent vaccinia virus, whereas JYNNEOS&#8482; is a replication-deficient modified vaccinia Ankara virus. ACAM2000<sup>&#174;</sup> shows some major cutaneous reactions, but JYNNEOS&#8482; does not show cutaneous reactions. Under Emergency Use Authorization (EUA), the Aventis Pasteur Smallpox Vaccine (APSV) can be used, but its effectiveness against Mpox is still unknown [<xref rid="B90-viruses-17-00753" ref-type="bibr">90</xref>].</p><p>The FDA (Food and Drug Administration) approved the use of the JYNNEOS&#8482; vaccine in 2019 to prevent smallpox and Mpox [<xref rid="B91-viruses-17-00753" ref-type="bibr">91</xref>]. Originally, the FDA developed these vaccines for the subcutaneous route in a two-dose series (0.5 mL per dose, administered 4 weeks apart). However, due to overwhelming demand, the FDA issued an Emergency Use Authorization (EUA) on 9 August 2022 for the intradermal route in a two-dose series (0.1 mL per dose, administered four weeks apart).</p><p>It was also found that full vaccination with the vaccine through subcutaneous, intradermal, and heterologous routes had an adjusted VE of 88.9% (95% CL, 56.0 to 97.2), 80.3% (95% CL, 22.9 to 95.0), and 86.9% (95% CL, 69.1 to 94.5), respectively. These vaccines are administered to persons who are either suffering from Mpox or have been previously exposed to such patients of Mpox. These vaccines (JYNNEOS&#8482;) are also offered to persons who are at high risk of getting infected by Mpox, such as gay, bisexual, MSM, transgender, non-binary, or gender non-conforming persons and HIV patients [<xref rid="B92-viruses-17-00753" ref-type="bibr">92</xref>].</p><p>Huber et al. have shown the effectiveness of the vaccine on patients suffering from Mpox and others with MSM (men who have sex with another man), aged 18&#8211;49. A total of 309 infected patients (Mpox or MSM) were included in this study and found that the adjusted vaccine efficiency (VE) was 75.2% (95% confidence interval (CL) 61.2 to 84.2) in patients with a single dose (partial vaccination) of vaccine and 85.9% (95% CL, 73.8 to 92.4) in patients with full (two doses) vaccination [<xref rid="B93-viruses-17-00753" ref-type="bibr">93</xref>].</p><p>Lauren Pischel quantified the vaccine efficacy of third-generation Mpox vaccines (MVA-BN, LC16m8, OrthopoxVac) in preventing infection, hospitalization, and death among the global population [<xref rid="B94-viruses-17-00753" ref-type="bibr">94</xref>]. They compared vaccinated individuals to those unvaccinated or vaccinated with other vaccines. Additionally, they analyzed vaccine efficacy based on the number of vaccine doses (one or two) and whether the vaccine was administered as post-exposure prophylaxis (PEP). A comprehensive literature search yielded 11,892 initial records, with an additional 3223 identified through citation tracking. Thirty-three studies focused on third-generation Mpox vaccines, predominantly MVA-BN (32 studies). Two additional studies reanalysed existing data. The majority of these studies cantered on gay, bisexual, or other men who have sex with men aged 18&#8211;49, conducted between May and October 2022.</p><p>Vaccine efficacy for a single dose of MVA-BN was estimated at 76% (95% CI: 64&#8211;88%) across twelve studies. For two doses, the vaccine efficacy was calculated at 82% (95% CI: 72&#8211;92%) based on six studies. Regarding post-exposure prophylaxis (PEP) with MVA-BN, the vaccine efficacy against Mpox was 20% (95% CI: -24&#8211;65%) from seven studies. All vaccine efficacy estimates were derived from random-effects meta-analysis.</p><p>In terms of study quality, 18 out of 33 (55%) were rated as poor, 3 out of 33 (9%) as fair, and 12 out of 33 (36%) as good. Notably, studies included in the meta-analysis generally exhibited higher quality, with 11 out of 16 (69%) rated as good.</p></sec><sec id="sec5dot2-viruses-17-00753"><title>5.2. Various Therapies for the Management of Mpox</title><sec id="sec5dot2dot1-viruses-17-00753"><title>5.2.1. Tecovirimat</title><p>Tecovirimat (TPOXX, ST-246) is generally used to treat smallpox, as recommended by the Food and Drug Administration (FDA), but under the Expanded Access Investigational New Drug (EA-IND) protocol, it can also be used to treat Mpox. In the United States or Canada, Tecovirimat is not approved for use against Mpox, although tecovirimat is now approved in Europe for the treatment of Mpox [<xref rid="B95-viruses-17-00753" ref-type="bibr">95</xref>,<xref rid="B96-viruses-17-00753" ref-type="bibr">96</xref>]. Various clinical trials are being conducted to evaluate the efficacy of tecovirimat, but it is not clear.</p><p>Tecovirimat is a small molecule virus inhibitor with strong activity against Mpox and other smallpox viruses. Tecovirimat&#8217;s mechanism involves targeting the highly conserved orthopoxvirus F13L protein. This protein is essential for the creation of enveloped virions, which are necessary for viral spread. Tecovirimat functions by acting as a molecular binder, promoting the dimerization of F13L and thereby inhibiting its normal activity [<xref rid="B97-viruses-17-00753" ref-type="bibr">97</xref>].</p><p>Early studies have indicated that tecovirimat did not significantly shorten the duration of monkeypox skin lesions [<xref rid="B98-viruses-17-00753" ref-type="bibr">98</xref>,<xref rid="B99-viruses-17-00753" ref-type="bibr">99</xref>]. Initial findings from the STOMP trial, which spanned multiple countries, failed to demonstrate a notable impact of tecovirimat on the healing time of skin and mucosal lesions in individuals with mild to moderate monkeypox. Notably, in the STOMP trial, a majority of participants began tecovirimat treatment more than five days after experiencing initial symptoms [<xref rid="B100-viruses-17-00753" ref-type="bibr">100</xref>]. According to another study [<xref rid="B101-viruses-17-00753" ref-type="bibr">101</xref>], tecovirimat, which inhibits the formation of p37 (a protein that helps in the release of enveloped virus and also enhances the virulence factor), was found to be effective in treating Mpox.</p><p>Tecovirimat is an inhibitor of the pox virus; however, Mpox also shows resistance against many drugs in cell culture, including CMX001 and ST-246 [<xref rid="B102-viruses-17-00753" ref-type="bibr">102</xref>]. The clinical study of Mpox was done in France in 2022, where Mpox was isolated and sequenced. This study reveals that the effective concentration of tecovirimat against Mpox is in nanomolar concentrations, while cidofovir is only effective at micromolar concentrations [<xref rid="B103-viruses-17-00753" ref-type="bibr">103</xref>]. Therefore, combination therapy may be effective for the treatment of Mpox.</p><p>The efficacy of tecovirimat has been evaluated in vitro and in vivo against a clade 2 Canadian 2022 isolate of Mpox isolated during the 2022 outbreak, and it was found that tecovirimat prevented Mpox replication in vitro with an effective concentration in the nanomolar range. The efficacy of tecovirimat was also evaluated in the CAST/EiJ mouse model with the 2022 Canadian isolate. The experiments also show that tecovirimat reduced viral titers after 1&#8211;2 weeks of infection. In 2022, tecovirimat was recommended against Mpox treatment. In vitro testing has been performed against 2022 Canadian isolates of Mpox designated Mpox/SP2833. The EC<sub>50</sub> and EC<sub>90</sub>, for TPOXX were determined against Mpox/SP2833, a clade 1 virus in Vero E6 cells is 0.008 &#177; 0.0014 (EC<sub>50</sub> value (&#956;M) &#177; SE) and 0.0145 &#177; 0.0138 (EC<sub>90</sub> value (&#956;M) &#177; SE) [<xref rid="B104-viruses-17-00753" ref-type="bibr">104</xref>].</p><p>In a recent study published in the Lancet journal in 2025, the author conducted an in vitro analysis comparing the susceptibility of clades 1b and 2b to tecovirimat. The clade 1b isolate was obtained in Sweden in August 2024 from a traveler returning from Africa. For comparison, the clade 2b virus was isolated in France in June 2022 from a patient at the Institut Pasteur Medical Center. Additionally, ancestral clades 1a and 2a were included as controls, utilizing U2OS cells, known for their high sensitivity to Mpox virus infection, as target cells. The findings demonstrated that tecovirimat effectively suppressed all four viral strains, exhibiting comparable half-maximal inhibitory concentrations (IC50s) ranging from 15.3 nM to 25.8 Nm [<xref rid="B105-viruses-17-00753" ref-type="bibr">105</xref>].</p></sec><sec id="sec5dot2dot2-viruses-17-00753"><title>5.2.2. Cidofovir and Brincidofovir</title><p>Brincidofovir and cidofovir are also being used as DNA polymerase inhibitors for Mpox treatment, despite not being approved by the FDA. In vitro and in vivo studies reported that both cidofovir and brincidofovir can stop the replication of Mpox [<xref rid="B106-viruses-17-00753" ref-type="bibr">106</xref>]. When Brin cidofovir derivative (CMX001) is given to the host, the lipid part of the drug breaks down and releases cidofovir, which forms cidofovir-diphosphate after phosphorylation, which inhibits DNA polymerase [<xref rid="B107-viruses-17-00753" ref-type="bibr">107</xref>,<xref rid="B108-viruses-17-00753" ref-type="bibr">108</xref>].</p><p>In a 2020 study, another new drug was reported, which is Nioch-14, having antiviral activity against Mpox [<xref rid="B106-viruses-17-00753" ref-type="bibr">106</xref>].</p></sec><sec id="sec5dot2dot3-viruses-17-00753"><title>5.2.3. Resveratrol</title><p>A recent study indicated that resveratrol plays an important role in Mpox treatment. Resveratrol (3,5,4&#8242;-trihydroxystilbene) is a natural polyphenol found in grapes, peanuts, pines, and berries [<xref rid="B109-viruses-17-00753" ref-type="bibr">109</xref>,<xref rid="B110-viruses-17-00753" ref-type="bibr">110</xref>]. It is also available in red and white wines, but a higher concentration is found in red wine. The maximum amount of resveratrol is found in Polygonum cuspidatum (524 &#956;g/g). It is also known as Japanese knotweed, which has been extensively used for inflammatory treatments in 2012&#8211;13. Resveratrol is found in cis and trans forms, but the trans form is highly effective in anti-inflammatory activity. The antiviral effects of resveratrol have been explored in several viruses, including the Mpox virus, the influenza A virus [<xref rid="B111-viruses-17-00753" ref-type="bibr">111</xref>] Epstein&#8211;Barr virus [<xref rid="B112-viruses-17-00753" ref-type="bibr">112</xref>], Herpes simplex virus [<xref rid="B113-viruses-17-00753" ref-type="bibr">113</xref>], HIV [<xref rid="B114-viruses-17-00753" ref-type="bibr">114</xref>], and hepatitis C virus [<xref rid="B115-viruses-17-00753" ref-type="bibr">115</xref>].</p><p>Resveratrol inhibits the replication of many viruses [<xref rid="B111-viruses-17-00753" ref-type="bibr">111</xref>,<xref rid="B115-viruses-17-00753" ref-type="bibr">115</xref>,<xref rid="B116-viruses-17-00753" ref-type="bibr">116</xref>,<xref rid="B117-viruses-17-00753" ref-type="bibr">117</xref>,<xref rid="B118-viruses-17-00753" ref-type="bibr">118</xref>,<xref rid="B119-viruses-17-00753" ref-type="bibr">119</xref>,<xref rid="B120-viruses-17-00753" ref-type="bibr">120</xref>]. The antiviral mechanisms of resveratrol against various types of viruses are different. Resveratrol reduced the virus yield by more than 120-fold at a concentration of 50 mM. The effect of resveratrol against Mpox has also been examined using HeLa cells. HeLa cells were infected with two strains of Mpox virus, Mpox-WA and Mpox-ROC, and it was found that resveratrol at 50 mM concentration reduced the yield of Mpox-WA and Mpox-ROC Clades by 195- and 38-fold, respectively [<xref rid="B121-viruses-17-00753" ref-type="bibr">121</xref>].</p><p>Apart from these potential therapies, some other alternative treatments such as TOP1 inhibitor, chlorhexidine, and cysteine proteinase inhibitors are being explored, but more investigation is required for the effective treatment of these compounds.</p></sec><sec id="sec5dot2dot4-viruses-17-00753"><title>5.2.4. Plant Metabolite as a Therapeutic Drug</title><p>A recent study was conducted in 2023, in which the anti-monkeypox capability was evaluated in 56 plant products. Among these metabolites, curcumin showed the strongest binding affinity with a value of &#8722;37.43 kcal/mol, followed by gedunin (&#8722;34.89 kcal/mol), piperine (&#8722;34.58 kcal/mol), and coumadin (&#8722;34.14 kcal/mol) [<xref rid="B122-viruses-17-00753" ref-type="bibr">122</xref>]. The study that occurred in 2022 shows various natural compounds obtained from Plantago lanceolate targeting on profilin-like protein A42R of Mpox virus [<xref rid="B123-viruses-17-00753" ref-type="bibr">123</xref>]. The A42R protein of Mpox has an amino acid sequence similarity with profilin proteins of eukaryotic cells [<xref rid="B124-viruses-17-00753" ref-type="bibr">124</xref>]. Profilin family proteins are actin-binding proteins responsible for F-actin assembly in the actin filament and also participate in the regulation of F-actin [<xref rid="B125-viruses-17-00753" ref-type="bibr">125</xref>]. Silico-based screening identified various important compounds, such as luteolin 7,30-diglucuronide, luteolin 7-glucuronide-30-glucoside, plantagoside, narcissoside, and others [<xref rid="B123-viruses-17-00753" ref-type="bibr">123</xref>]. The molecular dynamics simulation and post-simulation analysis revealed that plantagoside and narcissoside were found to be more stable products that were able to bind with the binding pocket of the viral protein of the Mpox virus due to hydrophobic and hydrogen interactions.</p></sec></sec></sec><sec sec-type="conclusions" id="sec6-viruses-17-00753"><title>6. Conclusions</title><p>Mpox, while historically less prevalent than other orthopoxviruses, has demonstrated a significant emergence for globally, highlighting the importance of robust surveillance and preparedness. Its complications, while often self-limiting, can be severe, particularly in immunocompromised individuals and children. Transmission, primarily through close contact, necessitates stringent public health measures to curtail outbreaks. Accurate and timely diagnosis, facilitated by PCR testing, is crucial for effective management and containment. While specific antiviral treatments are available, their accessibility and widespread use remain limited, emphasizing the need for further research and development. Effective public health strategies, including vaccination and education, are essential in mitigating the impact of Mpox and preventing future pandemics. Continued research into the virus&#8217;s evolving epidemiology, transmission dynamics, and optimal treatment strategies is imperative to safeguard global health.</p><p>The 2019 coronavirus pandemic demonstrated that disease outbreaks extend beyond physical illness, significantly affecting mental well-being. Individuals experienced heightened fear, including anxiety about potential loss and depression linked to isolation. Healthcare workers facing direct exposure reported particularly elevated levels of fear. Parallels can be drawn with the Mpox outbreak, which has also been associated with notable economic and behavioral shifts, manifesting in increased anger, frustration, depression, and anxiety.</p><p>The health care provider also has very little knowledge regarding the treatment of Mpox, so proper guidance and care of Mpox-affected people should be done for the management of mental health issues in COVID-19-affected people, WHO issued advisories that may be implemented in Mpox cases.</p><p>The important suggestions to control mental disorders during the monkeypox outbreak are as follows: (a) Always study and gain knowledge from an authorized source, such as WHO. (b) Do not come under the influence of people who are already suffering from any mental disorder because of an outbreak. (c) Avoid drinking alcohol or smoking during an outbreak because it will only ruin your health condition. (d) Hand hygiene practices should be followed regularly. (e) Eat a well-balanced diet, and try to avoid sitting alone. Even when you are alone in the house, try to chat with your friends or family members via social media. (f) Exercise daily.</p><p>The outbreaks in 2022 across the globe have emphasized the significance of continuous and focused intensive care, along with the development of novel drugs.</p><p>The limited smallpox vaccine administration and decreasing immunity in the population can enhance virus spreading globally. Patients of Mpox have different kinds of complications, such as bacterial infection of the skin, skin scarring, permanent corneal scarring, pneumonia, dehydration, sepsis, and encephalitis. It is imperative to provide comprehensive care for patients, including education, nutritional support, hydration, and protection of sensitive organs such as the eyes and genitals. Therefore, it is important for the medical professional team, including clinicians, health experts, and nurses, to immediately identify infection in humans and animals, use protective measures, and initiate public health reporting to prevent an outbreak. </p></sec></body><back><ack><title>Acknowledgments</title><p>We thank Sharda University and Imam Mohammad Ibn Saud Islamic University (IMSIU) for providing valuable resources for this work.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization and original draft preparation: R.Y., U.S. and S.K.; writing: R.Y., U.S., S.G., H.A.R., A.A.C., S.R. and V.K.K.; review and editing: H.A.R., A.A.C. and S.R.; supervision: S.K., V.K.K. and R.Y. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-17-00753"><label>1.</label><element-citation publication-type="webpage"><article-title>Multi-Country Outbreak of Mpox, External Situation Report #51&#8212;29 April 2025</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report--51---29-april-2025" ext-link-type="uri">https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report--51---29-april-2025</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-05-20">(accessed on 20 May 2025)</date-in-citation></element-citation></ref><ref id="B2-viruses-17-00753"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>K.</given-names></name><name name-style="western"><surname>Leggat</surname><given-names>P.A.</given-names></name></person-group><article-title>Human Monkeypox: Current State of Knowledge and Implications for the Future</article-title><source>Trop. Med. Infect. Dis.</source><year>2016</year><volume>1</volume><elocation-id>8</elocation-id><pub-id pub-id-type="doi">10.3390/tropicalmed1010008</pub-id><pub-id pub-id-type="pmid">30270859</pub-id><pub-id pub-id-type="pmcid">PMC6082047</pub-id></element-citation></ref><ref id="B3-viruses-17-00753"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCollum</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Damon</surname><given-names>I.K.</given-names></name></person-group><article-title>Human Monkeypox</article-title><source>Clin. Infect. Dis.</source><year>2014</year><volume>58</volume><fpage>260</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1093/cid/cit703</pub-id><pub-id pub-id-type="pmid">24158414</pub-id><pub-id pub-id-type="pmcid">PMC5895105</pub-id></element-citation></ref><ref id="B4-viruses-17-00753"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bunge</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Hoet</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lienert</surname><given-names>F.</given-names></name><name name-style="western"><surname>Weidenthaler</surname><given-names>H.</given-names></name><name name-style="western"><surname>Baer</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Steffen</surname><given-names>R.</given-names></name></person-group><article-title>The Changing Epidemiology of Human Monkeypox&#8212;A Potential Threat? A Systematic Review</article-title><source>PLoS Neglected Trop. Dis.</source><year>2022</year><volume>16</volume><elocation-id>e0010141</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0010141</pub-id><pub-id pub-id-type="pmcid">PMC8870502</pub-id><pub-id pub-id-type="pmid">35148313</pub-id></element-citation></ref><ref id="B5-viruses-17-00753"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shchelkunov</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Totmenin</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Babkin</surname><given-names>I.V.</given-names></name><name name-style="western"><surname>Safronov</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Ryazankina</surname><given-names>O.I.</given-names></name><name name-style="western"><surname>Petrov</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Gutorov</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Uvarova</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Mikheev</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Sisler</surname><given-names>J.R.</given-names></name><etal/></person-group><article-title>Human Monkeypox and Smallpox Viruses: Genomic Comparison</article-title><source>FEBS Lett.</source><year>2001</year><volume>509</volume><fpage>66</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(01)03144-1</pub-id><pub-id pub-id-type="pmid">11734207</pub-id><pub-id pub-id-type="pmcid">PMC9533818</pub-id></element-citation></ref><ref id="B6-viruses-17-00753"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shchelkunov</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Massung</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>J.J.</given-names></name></person-group><article-title>Comparison of the Genome DNA Sequences of Bangladesh-1975 and India-1967 Variola Viruses</article-title><source>Virus Res.</source><year>1995</year><volume>36</volume><fpage>107</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/0168-1702(94)00113-Q</pub-id><pub-id pub-id-type="pmid">7625123</pub-id></element-citation></ref><ref id="B7-viruses-17-00753"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hendrickson</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hatcher</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Lefkowitz</surname><given-names>E.J.</given-names></name></person-group><article-title>Orthopoxvirus Genome Evolution: The Role of Gene Loss</article-title><source>Viruses</source><year>2010</year><volume>2</volume><fpage>1933</fpage><lpage>1967</lpage><pub-id pub-id-type="doi">10.3390/v2091933</pub-id><pub-id pub-id-type="pmid">21994715</pub-id><pub-id pub-id-type="pmcid">PMC3185746</pub-id></element-citation></ref><ref id="B8-viruses-17-00753"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Witt</surname><given-names>A.S.A.</given-names></name><name name-style="western"><surname>de Trindade</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>de Souza</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Serafim</surname><given-names>M.S.M.</given-names></name><name name-style="western"><surname>da Costa</surname><given-names>A.V.B.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>M.V.F.</given-names></name><name name-style="western"><surname>de Melo Iani</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>R.A.L.</given-names></name><name name-style="western"><surname>Kroon</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Abrah&#227;o</surname><given-names>J.S.</given-names></name></person-group><article-title>Ultrastructural Analysis of Monkeypox Virus Replication in Vero Cells</article-title><source>J. Med. Virol.</source><year>2023</year><volume>95</volume><fpage>e28536</fpage><pub-id pub-id-type="doi">10.1002/jmv.28536</pub-id><pub-id pub-id-type="pmid">36708101</pub-id></element-citation></ref><ref id="B9-viruses-17-00753"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lapa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Carletti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mazzotta</surname><given-names>V.</given-names></name><name name-style="western"><surname>Matusali</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pinnetti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Meschi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gagliardini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Colavita</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mondi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Minosse</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Monkeypox Virus Isolation from a Semen Sample Collected in the Early Phase of Infection in a Patient with Prolonged Seminal Viral Shedding</article-title><source>Lancet Infect. Dis.</source><year>2022</year><volume>22</volume><fpage>1267</fpage><lpage>1269</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00513-8</pub-id><pub-id pub-id-type="pmid">35931095</pub-id><pub-id pub-id-type="pmcid">PMC9629691</pub-id></element-citation></ref><ref id="B10-viruses-17-00753"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moss</surname><given-names>B.</given-names></name></person-group><article-title>Understanding the Biology of Monkeypox Virus to Prevent Future Outbreaks</article-title><source>Nat. Microbiol.</source><year>2024</year><volume>9</volume><fpage>1408</fpage><lpage>1416</lpage><pub-id pub-id-type="doi">10.1038/s41564-024-01690-1</pub-id><pub-id pub-id-type="pmid">38724757</pub-id></element-citation></ref><ref id="B11-viruses-17-00753"><label>11.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Mathieu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Spooner</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dattani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>H.</given-names></name><name name-style="western"><surname>Roser</surname><given-names>M.</given-names></name></person-group><article-title>Mpox</article-title><publisher-name>Our World in Data</publisher-name><year>2022</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ourworldindata.org/mpox" ext-link-type="uri">https://ourworldindata.org/mpox</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-05-01">(accessed on 1 May 2022)</date-in-citation></element-citation></ref><ref id="B12-viruses-17-00753"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masirika</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Udahemuka</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Schuele</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ndishimye</surname><given-names>P.</given-names></name><name name-style="western"><surname>Otani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mbiribindi</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Marekani</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Mambo</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Bubala</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Boter</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Ongoing Mpox Outbreak in Kamituga, South Kivu Province, Associated with Monkeypox Virus of a Novel Clade I Sub-Lineage, Democratic Republic of the Congo, 2024</article-title><source>Euro Surveill.</source><year>2024</year><volume>29</volume><fpage>2400106</fpage><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2024.29.11.2400106</pub-id><pub-id pub-id-type="pmid">38487886</pub-id><pub-id pub-id-type="pmcid">PMC10941309</pub-id></element-citation></ref><ref id="B13-viruses-17-00753"><label>13.</label><element-citation publication-type="webpage"><article-title>Preliminary Analysis of Full Genome Sequences of 58 MPXV Clade Ib Cases from Kamituga and Kamanyola, South-Kivu, DRC &#8212;MPXV/Evolution</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://virological.org/t/preliminary-analysis-of-full-genome-sequences-of-58-mpxv-clade-ib-cases-from-kamituga-and-kamanyola-south-kivu-drc/975" ext-link-type="uri">https://virological.org/t/preliminary-analysis-of-full-genome-sequences-of-58-mpxv-clade-ib-cases-from-kamituga-and-kamanyola-south-kivu-drc/975</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-04-10">(accessed on 10 April 2025)</date-in-citation></element-citation></ref><ref id="B14-viruses-17-00753"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ndembi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Folayan</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Ngongo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ntoumi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ogoina</surname><given-names>D.</given-names></name><name name-style="western"><surname>El Rabbat</surname><given-names>M.</given-names></name><name name-style="western"><surname>Okwo-Bele</surname><given-names>J.-M.</given-names></name><name name-style="western"><surname>Kaseya</surname><given-names>J.</given-names></name></person-group><article-title>Mpox Outbreaks in Africa Constitute a Public Health Emergency of Continental Security</article-title><source>Lancet Glob. Health</source><year>2024</year><volume>12</volume><fpage>e1577</fpage><lpage>e1579</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(24)00363-2</pub-id><pub-id pub-id-type="pmid">39178878</pub-id></element-citation></ref><ref id="B15-viruses-17-00753"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nazli Khatib</surname><given-names>M.</given-names></name><name name-style="western"><surname>Datt Sharma</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pratap Singh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bushi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ballal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bhat</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ndabashinze</surname><given-names>R.</given-names></name></person-group><article-title>Mpox 2024: New Variant, New Challenges, and the Looming Pandemic</article-title><source>Clin. Infect. Pract.</source><year>2024</year><volume>24</volume><fpage>100394</fpage><pub-id pub-id-type="doi">10.1016/j.clinpr.2024.100394</pub-id></element-citation></ref><ref id="B16-viruses-17-00753"><label>16.</label><element-citation publication-type="webpage"><article-title>Multi-Country Outbreak of Mpox, External Situation Report#35&#8212;12 August 2024</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report-35--12-august-2024" ext-link-type="uri">https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report-35--12-august-2024</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-04-10">(accessed on 10 April 2025)</date-in-citation></element-citation></ref><ref id="B17-viruses-17-00753"><label>17.</label><element-citation publication-type="webpage"><article-title>One Case of Mpox Clade 1 Reported in Sweden&#8212;The Public Health Agency of Sweden</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.folkhalsomyndigheten.se/the-public-health-agency-of-sweden/communicable-disease-control/disease-information-about-mpox/one-case-of-mpox-clade-i-reported-in-sweden/" ext-link-type="uri">https://www.folkhalsomyndigheten.se/the-public-health-agency-of-sweden/communicable-disease-control/disease-information-about-mpox/one-case-of-mpox-clade-i-reported-in-sweden/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-04-10">(accessed on 10 April 2025)</date-in-citation></element-citation></ref><ref id="B18-viruses-17-00753"><label>18.</label><element-citation publication-type="webpage"><article-title>Thailand Confirms Asia&#8217;s First Known Case of New Deadlier Mpox Variant</article-title><source>The Guardian</source><year>2024</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.theguardian.com/world/article/2024/aug/23/thailand-mpox-clade-1b-strain-new-variant-case" ext-link-type="uri">https://www.theguardian.com/world/article/2024/aug/23/thailand-mpox-clade-1b-strain-new-variant-case</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-08-23">(accessed on 23 August 2023)</date-in-citation></element-citation></ref><ref id="B19-viruses-17-00753"><label>19.</label><element-citation publication-type="gov"><article-title>CDC Mpox in the United States and Around the World: Current Situation</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/mpox/situation-summary/index.html" ext-link-type="uri">https://www.cdc.gov/mpox/situation-summary/index.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-25">(accessed on 25 February 2025)</date-in-citation></element-citation></ref><ref id="B20-viruses-17-00753"><label>20.</label><element-citation publication-type="webpage"><article-title>Situation Report: Mpox Multi-Country Outbreak&#8212;Region of the Americas&#8212;31 January 2025&#8212;PAHO/WHO|Pan American Health Organization</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.paho.org/en/documents/situation-report-mpox-multi-country-outbreak-region-americas-31-january-2025" ext-link-type="uri">https://www.paho.org/en/documents/situation-report-mpox-multi-country-outbreak-region-americas-31-january-2025</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-25">(accessed on 25 February 2025)</date-in-citation></element-citation></ref><ref id="B21-viruses-17-00753"><label>21.</label><element-citation publication-type="webpage"><article-title>Mpox</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news-room/fact-sheets/detail/mpox" ext-link-type="uri">https://www.who.int/news-room/fact-sheets/detail/mpox</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-25">(accessed on 25 February 2025)</date-in-citation></element-citation></ref><ref id="B22-viruses-17-00753"><label>22.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Rathish</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zahra</surname><given-names>F.</given-names></name></person-group><source>Mpox (Monkeypox)</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2024</year><pub-id pub-id-type="pmid">34662033</pub-id></element-citation></ref><ref id="B23-viruses-17-00753"><label>23.</label><element-citation publication-type="book"><article-title>Monkeypox</article-title><publisher-name>World Health Organization (WHO)</publisher-name><year>2022</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news-room/fact-sheets/detail/mpox" ext-link-type="uri">https://www.who.int/news-room/fact-sheets/detail/mpox</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-05-25">(accessed on 25 May 2022)</date-in-citation></element-citation></ref><ref id="B24-viruses-17-00753"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Acharya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gendelman</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Byrareddy</surname><given-names>S.N.</given-names></name></person-group><article-title>The 2022 Outbreak and the Pathobiology of the Monkeypox Virus</article-title><source>J. Autoimmun.</source><year>2022</year><volume>131</volume><fpage>102855</fpage><pub-id pub-id-type="doi">10.1016/j.jaut.2022.102855</pub-id><pub-id pub-id-type="pmid">35760647</pub-id><pub-id pub-id-type="pmcid">PMC9534147</pub-id></element-citation></ref><ref id="B25-viruses-17-00753"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laurenson-Schafer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sklenovsk&#225;</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hoxha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Ndumbi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fitzner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Almiron</surname><given-names>M.</given-names></name><name name-style="western"><surname>de Sousa</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Briand</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cenciarelli</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Description of the First Global Outbreak of Mpox: An Analysis of Global Surveillance Data</article-title><source>Lancet Glob. Health</source><year>2023</year><volume>11</volume><fpage>e1012</fpage><lpage>e1023</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(23)00198-5</pub-id><pub-id pub-id-type="pmid">37349031</pub-id><pub-id pub-id-type="pmcid">PMC10281644</pub-id></element-citation></ref><ref id="B26-viruses-17-00753"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thornhill</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Barkati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Walmsley</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rockstroh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Antinori</surname><given-names>A.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Palich</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nori</surname><given-names>A.</given-names></name><name name-style="western"><surname>Reeves</surname><given-names>I.</given-names></name><name name-style="western"><surname>Habibi</surname><given-names>M.S.</given-names></name><etal/></person-group><article-title>Monkeypox Virus Infection in Humans across 16 Countries&#8212;April&#8211;June 2022</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>387</volume><fpage>679</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2207323</pub-id><pub-id pub-id-type="pmid">35866746</pub-id></element-citation></ref><ref id="B27-viruses-17-00753"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perez Duque</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Martins</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Casaca</surname><given-names>P.</given-names></name><name name-style="western"><surname>Leite</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Tavares</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mansinho</surname><given-names>K.</given-names></name><name name-style="western"><surname>Duque</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cordeiro</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Ongoing Monkeypox Virus Outbreak, Portugal, 29 April to 23 May 2022</article-title><source>Euro Surveill.</source><year>2022</year><volume>27</volume><fpage>2200424</fpage><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2022.27.22.2200424</pub-id><pub-id pub-id-type="pmid">35656830</pub-id><pub-id pub-id-type="pmcid">PMC9164676</pub-id></element-citation></ref><ref id="B28-viruses-17-00753"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez-Morales</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Lopardo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Verbanaz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Orduna</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lloveras</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aze&#241;as-Burgoa</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Escalera-Antezana</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Alvarado-Arnez</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Barbosa</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Diaz-Quijano</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Latin America: Situation and Preparedness Facing the Multi-Country Human Monkeypox Outbreak</article-title><source>Lancet Reg. Health Am.</source><year>2022</year><volume>13</volume><fpage>100318</fpage><pub-id pub-id-type="doi">10.1016/j.lana.2022.100318</pub-id><pub-id pub-id-type="pmid">35813461</pub-id><pub-id pub-id-type="pmcid">PMC9257677</pub-id></element-citation></ref><ref id="B29-viruses-17-00753"><label>29.</label><element-citation publication-type="webpage"><article-title>The WHO Declaration of Monkeypox as a Global Public Health Emergency|Infectious Diseases|JAMA|JAMA Network</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://jamanetwork.com/journals/jama/fullarticle/2794922" ext-link-type="uri">https://jamanetwork.com/journals/jama/fullarticle/2794922</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-02-10">(accessed on 10 February 2024)</date-in-citation></element-citation></ref><ref id="B30-viruses-17-00753"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harris</surname><given-names>E.</given-names></name></person-group><article-title>What to Know About Monkeypox</article-title><source>JAMA</source><year>2022</year><volume>327</volume><fpage>2278</fpage><lpage>2279</lpage><pub-id pub-id-type="doi">10.1001/jama.2022.9499</pub-id><pub-id pub-id-type="pmid">35622356</pub-id></element-citation></ref><ref id="B31-viruses-17-00753"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaughan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aarons</surname><given-names>E.</given-names></name><name name-style="western"><surname>Astbury</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chand</surname><given-names>M.</given-names></name><name name-style="western"><surname>Flegg</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hardman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Harper</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jarvis</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mawdsley</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Human-to-Human Transmission of Monkeypox Virus, United Kingdom, October 2018</article-title><source>Emerg. Infect. Dis.</source><year>2020</year><volume>26</volume><fpage>782</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.3201/eid2604.191164</pub-id><pub-id pub-id-type="pmid">32023204</pub-id><pub-id pub-id-type="pmcid">PMC7101111</pub-id></element-citation></ref><ref id="B32-viruses-17-00753"><label>32.</label><element-citation publication-type="webpage"><article-title>Multi-Country Monkeypox Outbreak in Non-Endemic Countries</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON385" ext-link-type="uri">https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON385</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-10">(accessed on 10 February 2025)</date-in-citation></element-citation></ref><ref id="B33-viruses-17-00753"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okyay</surname><given-names>R.A.</given-names></name></person-group><article-title>Another Epidemic in the Shadow of COVID 19 Pandemic: A Review of Monkeypox</article-title><source>EJMO</source><year>2022</year><volume>6</volume><fpage>95</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.14744/ejmo.2022.2022</pub-id></element-citation></ref><ref id="B34-viruses-17-00753"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mbala</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Huggins</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Riu-Rovira</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ahuka</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Mulembakani</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rimoin</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Muyembe</surname><given-names>J.-J.T.</given-names></name></person-group><article-title>Maternal and Fetal Outcomes Among Pregnant Women With Human Monkeypox Infection in the Democratic Republic of Congo</article-title><source>J. Infect. Dis.</source><year>2017</year><volume>216</volume><fpage>824</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1093/infdis/jix260</pub-id><pub-id pub-id-type="pmid">29029147</pub-id></element-citation></ref><ref id="B35-viruses-17-00753"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogoina</surname><given-names>D.</given-names></name><name name-style="western"><surname>Iroezindu</surname><given-names>M.</given-names></name><name name-style="western"><surname>James</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Oladokun</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yinka-Ogunleye</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wakama</surname><given-names>P.</given-names></name><name name-style="western"><surname>Otike-Odibi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Usman</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Obazee</surname><given-names>E.</given-names></name><name name-style="western"><surname>Aruna</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Clinical Course and Outcome of Human Monkeypox in Nigeria</article-title><source>Clin. Infect. Dis.</source><year>2020</year><volume>71</volume><fpage>e210</fpage><lpage>e214</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa143</pub-id><pub-id pub-id-type="pmid">32052029</pub-id></element-citation></ref><ref id="B36-viruses-17-00753"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badenoch</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Conti</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rengasamy</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Watson</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Butler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rooney</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Zandi</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Neurological and Psychiatric Presentations Associated with Human Monkeypox Virus Infection: A Systematic Review and Meta-Analysis</article-title><source>EClinicalMedicine</source><year>2022</year><volume>52</volume><fpage>101644</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2022.101644</pub-id><pub-id pub-id-type="pmid">36246957</pub-id><pub-id pub-id-type="pmcid">PMC9533950</pub-id></element-citation></ref><ref id="B37-viruses-17-00753"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmed</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Abdulqadir</surname><given-names>S.O.</given-names></name><name name-style="western"><surname>Hussein</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Omar</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Essa</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Dhama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lorenzo</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Abdulla</surname><given-names>A.Q.</given-names></name></person-group><article-title>The Impact of Monkeypox Outbreak on Mental Health and Counteracting Strategies: A Call to Action</article-title><source>Int. J. Surg.</source><year>2022</year><volume>106</volume><fpage>106943</fpage><pub-id pub-id-type="doi">10.1016/j.ijsu.2022.106943</pub-id><pub-id pub-id-type="pmid">36155257</pub-id><pub-id pub-id-type="pmcid">PMC9533932</pub-id></element-citation></ref><ref id="B38-viruses-17-00753"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmed</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Abdulqadir</surname><given-names>S.O.</given-names></name><name name-style="western"><surname>Omar</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Abdullah</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Hussein</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Mohammed Amin</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Chandran</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Dhama</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Knowledge, Attitude and Worry in the Kurdistan Region of Iraq during the Mpox (Monkeypox) Outbreak in 2022: An Online Cross-Sectional Study</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>610</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11030610</pub-id><pub-id pub-id-type="pmid">36992194</pub-id><pub-id pub-id-type="pmcid">PMC10054073</pub-id></element-citation></ref><ref id="B39-viruses-17-00753"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abaza</surname><given-names>H.</given-names></name><name name-style="western"><surname>Agadi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Anand</surname><given-names>A.</given-names></name><name name-style="western"><surname>Elsaid</surname><given-names>M.</given-names></name></person-group><article-title>Clinical Manifestations of Monkeypox</article-title><source>Adv. Exp. Med. Biol.</source><year>2023</year><volume>1410</volume><fpage>7</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1007/5584_2022_747</pub-id><pub-id pub-id-type="pmid">36396927</pub-id></element-citation></ref><ref id="B40-viruses-17-00753"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lun</surname><given-names>W.</given-names></name></person-group><article-title>Skin Manifestation of Human Monkeypox</article-title><source>J. Clin. Med.</source><year>2023</year><volume>12</volume><elocation-id>914</elocation-id><pub-id pub-id-type="doi">10.3390/jcm12030914</pub-id><pub-id pub-id-type="pmid">36769562</pub-id><pub-id pub-id-type="pmcid">PMC9918194</pub-id></element-citation></ref><ref id="B41-viruses-17-00753"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>A.</given-names></name><name name-style="western"><surname>Flores</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kheiri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Desrosiers</surname><given-names>D.</given-names></name></person-group><article-title>Monkeypox: A Comprehensive Review of Transmission, Pathogenesis, and Manifestation</article-title><source>Cureus</source><year>2022</year><volume>14</volume><fpage>e26531</fpage><pub-id pub-id-type="doi">10.7759/cureus.26531</pub-id><pub-id pub-id-type="pmid">35928395</pub-id><pub-id pub-id-type="pmcid">PMC9345383</pub-id></element-citation></ref><ref id="B42-viruses-17-00753"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>R.-M.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.-J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>L.-Z.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B.-P.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.-M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z.-D.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>J.-K.</given-names></name><etal/></person-group><article-title>Diagnosis, Treatment, and Prevention of Monkeypox in Children: An Experts&#8217; Consensus Statement</article-title><source>World J. Pediatr.</source><year>2023</year><volume>19</volume><fpage>231</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1007/s12519-022-00624-3</pub-id><pub-id pub-id-type="pmid">36409451</pub-id><pub-id pub-id-type="pmcid">PMC9685019</pub-id></element-citation></ref><ref id="B43-viruses-17-00753"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Issa</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Alkhofash</surname><given-names>N.F.</given-names></name><name name-style="western"><surname>Gopinath</surname><given-names>D.</given-names></name><name name-style="western"><surname>Varma</surname><given-names>S.R.</given-names></name></person-group><article-title>Oral Manifestations in Monkeypox: A Scoping Review on Implications for Oral Health</article-title><source>Dent. J.</source><year>2023</year><volume>11</volume><elocation-id>132</elocation-id><pub-id pub-id-type="doi">10.3390/dj11050132</pub-id><pub-id pub-id-type="pmcid">PMC10217612</pub-id><pub-id pub-id-type="pmid">37232783</pub-id></element-citation></ref><ref id="B44-viruses-17-00753"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Girometti</surname><given-names>N.</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bracchi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heskin</surname><given-names>J.</given-names></name><name name-style="western"><surname>McOwan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tittle</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gedela</surname><given-names>K.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>C.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gohil</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Demographic and Clinical Characteristics of Confirmed Human Monkeypox Virus Cases in Individuals Attending a Sexual Health Centre in London, UK: An Observational Analysis</article-title><source>Lancet Infect. Dis.</source><year>2022</year><volume>22</volume><fpage>1321</fpage><lpage>1328</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00411-X</pub-id><pub-id pub-id-type="pmid">35785793</pub-id><pub-id pub-id-type="pmcid">PMC9534773</pub-id></element-citation></ref><ref id="B45-viruses-17-00753"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Griffiths-Acha</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vela-Ganuza</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sarr&#243;-Fuente</surname><given-names>C.</given-names></name><name name-style="western"><surname>L&#243;pez-Estebaranz</surname><given-names>J.L.</given-names></name></person-group><article-title>Monkeypox: A New Differential Diagnosis When Addressing Genital Ulcer Disease</article-title><source>Br. J. Dermatol.</source><year>2022</year><volume>187</volume><fpage>1050</fpage><lpage>1052</lpage><pub-id pub-id-type="doi">10.1111/bjd.21834</pub-id><pub-id pub-id-type="pmid">35977429</pub-id></element-citation></ref><ref id="B46-viruses-17-00753"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prasad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Galvan Casas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Strahan</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Fuller</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Peebles</surname><given-names>K.</given-names></name><name name-style="western"><surname>Carugno</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leslie</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Harp</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Pumnea</surname><given-names>T.</given-names></name><name name-style="western"><surname>McMahon</surname><given-names>D.E.</given-names></name><etal/></person-group><article-title>A Dermatologic Assessment of 101 Mpox (Monkeypox) Cases from 13 Countries during the 2022 Outbreak: Skin Lesion Morphology, Clinical Course, and Scarring</article-title><source>J. Am. Acad. Dermatol.</source><year>2023</year><volume>88</volume><fpage>1066</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2022.12.035</pub-id><pub-id pub-id-type="pmid">36641010</pub-id><pub-id pub-id-type="pmcid">PMC9833815</pub-id></element-citation></ref><ref id="B47-viruses-17-00753"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raffaele</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Baldo</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Santana</surname><given-names>G.U.</given-names></name><name name-style="western"><surname>da Costa</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Palma</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Campos</surname><given-names>L.</given-names></name></person-group><article-title>Phototherapies for the Management of a Large Painful Facial Cutaneous Lesion from Human Monkeypox Infection</article-title><source>Photodiagnosis Photodyn. Ther.</source><year>2023</year><volume>41</volume><fpage>103276</fpage><pub-id pub-id-type="doi">10.1016/j.pdpdt.2023.103276</pub-id><pub-id pub-id-type="pmid">36632872</pub-id><pub-id pub-id-type="pmcid">PMC9827753</pub-id></element-citation></ref><ref id="B48-viruses-17-00753"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>M.S.T.</given-names></name><name name-style="western"><surname>dos Santos</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Coutinho</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>M.P.D.</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Veloso</surname><given-names>V.G.</given-names></name><name name-style="western"><surname>Grinsztejn</surname><given-names>B.</given-names></name></person-group><article-title>The First Case of Acute HIV and Monkeypox Coinfection in Latin America</article-title><source>Braz. J. Infect. Dis.</source><year>2022</year><volume>27</volume><fpage>102736</fpage><pub-id pub-id-type="doi">10.1016/j.bjid.2022.102736</pub-id><pub-id pub-id-type="pmid">36592945</pub-id><pub-id pub-id-type="pmcid">PMC9800211</pub-id></element-citation></ref><ref id="B49-viruses-17-00753"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Sousa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Patroc&#237;nio</surname><given-names>J.</given-names></name><name name-style="western"><surname>Frade</surname><given-names>J.</given-names></name><name name-style="western"><surname>Correia</surname><given-names>C.</given-names></name><name name-style="western"><surname>Borges-Costa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Filipe</surname><given-names>P.</given-names></name></person-group><article-title>Human Monkeypox Coinfection with Acute HIV: An Exuberant Presentation</article-title><source>Int. J. STD AIDS</source><year>2022</year><volume>33</volume><fpage>936</fpage><lpage>938</lpage><pub-id pub-id-type="doi">10.1177/09564624221114998</pub-id><pub-id pub-id-type="pmid">35822910</pub-id></element-citation></ref><ref id="B50-viruses-17-00753"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ortiz-Saavedra</surname><given-names>B.</given-names></name><name name-style="western"><surname>Montes-Madariaga</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Cabanillas-Ramirez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Alva</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ricardo-Mart&#237;nez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Le&#243;n-Figueroa</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Barboza</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Mohanty</surname><given-names>A.</given-names></name><name name-style="western"><surname>Padhi</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Sah</surname><given-names>R.</given-names></name></person-group><article-title>Epidemiologic Situation of HIV and Monkeypox Coinfection: A Systematic Review</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>246</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11020246</pub-id><pub-id pub-id-type="pmid">36851124</pub-id><pub-id pub-id-type="pmcid">PMC9965118</pub-id></element-citation></ref><ref id="B51-viruses-17-00753"><label>51.</label><element-citation publication-type="webpage"><article-title>Multi-Country Outbreak of Mpox, External Situation Report#12&#8212;14 December 2022</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report-12--14-december-2022" ext-link-type="uri">https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report-12--14-december-2022</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B52-viruses-17-00753"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>von Magnus</surname><given-names>P.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Birch-Andersen</surname><given-names>A.</given-names></name></person-group><article-title>A Pox-Like Disease in Cynomolgus Monkeys</article-title><source>Acta Pathol. Microbiol. Scand.</source><year>1959</year><volume>46</volume><fpage>156</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1111/j.1699-0463.1959.tb00328.x</pub-id></element-citation></ref><ref id="B53-viruses-17-00753"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>I.F.</given-names></name><name name-style="western"><surname>Royce</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Kazembe</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dyer</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Daly</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Zimba</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vernazza</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Maida</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fiscus</surname><given-names>S.A.</given-names></name><etal/></person-group><article-title>Reduction of Concentration of HIV-1 in Semen after Treatment of Urethritis: Implications for Prevention of Sexual Transmission of HIV-1. AIDSCAP Malawi Research Group</article-title><source>Lancet</source><year>1997</year><volume>349</volume><fpage>1868</fpage><lpage>1873</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(97)02190-9</pub-id><pub-id pub-id-type="pmid">9217758</pub-id></element-citation></ref><ref id="B54-viruses-17-00753"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gray</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Wawer</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Brookmeyer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sewankambo</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Serwadda</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wabwire-Mangen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lutalo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>vanCott</surname><given-names>T.</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>T.C.</given-names></name><etal/></person-group><article-title>Probability of HIV-1 Transmission per Coital Act in Monogamous, Heterosexual, HIV-1-Discordant Couples in Rakai, Uganda</article-title><source>Lancet</source><year>2001</year><volume>357</volume><fpage>1149</fpage><lpage>1153</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)04331-2</pub-id><pub-id pub-id-type="pmid">11323041</pub-id></element-citation></ref><ref id="B55-viruses-17-00753"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitj&#224;</surname><given-names>O.</given-names></name><name name-style="western"><surname>Alemany</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marks</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mora</surname><given-names>J.I.L.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Aldama</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>M.S.T.</given-names></name><name name-style="western"><surname>Herrera</surname><given-names>E.A.C.</given-names></name><name name-style="western"><surname>Crabtree-Ramirez</surname><given-names>B.</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Girometti</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Mpox in People with Advanced HIV Infection: A Global Case Series</article-title><source>Lancet</source><year>2023</year><volume>401</volume><fpage>939</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(23)00273-8</pub-id><pub-id pub-id-type="pmid">36828001</pub-id></element-citation></ref><ref id="B56-viruses-17-00753"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez-Nava</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kadlecik</surname><given-names>P.</given-names></name><name name-style="western"><surname>Filardo</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Ain</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>McCormick</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Webber</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>O&#8217;Laughlin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Petersen</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Narasimhan</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Myocarditis Attributable to Monkeypox Virus Infection in 2 Patients, United States, 2022</article-title><source>Emerg. Infect. Dis.</source><year>2022</year><volume>28</volume><fpage>2508</fpage><lpage>2512</lpage><pub-id pub-id-type="doi">10.3201/eid2812.221276</pub-id><pub-id pub-id-type="pmid">36179413</pub-id><pub-id pub-id-type="pmcid">PMC9707588</pub-id></element-citation></ref><ref id="B57-viruses-17-00753"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kelleman</surname><given-names>M.</given-names></name><name name-style="western"><surname>West</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Peter</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dove</surname><given-names>M.</given-names></name><name name-style="western"><surname>Butto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oster</surname><given-names>M.E.</given-names></name></person-group><article-title>Comparison of Multisystem Inflammatory Syndrome in Children-Related Myocarditis, Classic Viral Myocarditis, and COVID-19 Vaccine-Related Myocarditis in Children</article-title><source>J. Am. Heart Assoc.</source><year>2022</year><volume>11</volume><fpage>e024393</fpage><pub-id pub-id-type="doi">10.1161/JAHA.121.024393</pub-id><pub-id pub-id-type="pmid">35475362</pub-id><pub-id pub-id-type="pmcid">PMC9238597</pub-id></element-citation></ref><ref id="B58-viruses-17-00753"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mora</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Sperling</surname><given-names>L.S.</given-names></name></person-group><article-title>Cardiac Complications after Smallpox Vaccination</article-title><source>South. Med. J.</source><year>2009</year><volume>102</volume><fpage>615</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1097/SMJ.0b013e31819fe55b</pub-id><pub-id pub-id-type="pmid">19434043</pub-id></element-citation></ref><ref id="B59-viruses-17-00753"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maqbool</surname><given-names>K.U.</given-names></name><name name-style="western"><surname>Arsh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Veena</surname><given-names>F.</given-names></name><name name-style="western"><surname>Punshi</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Payal</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rani</surname><given-names>D.</given-names></name><name name-style="western"><surname>Malik</surname><given-names>J.</given-names></name></person-group><article-title>Cardiovascular Manifestations of Human Monkeypox Virus: An Updated Review</article-title><source>Curr. Probl. Cardiol.</source><year>2023</year><volume>48</volume><fpage>101869</fpage><pub-id pub-id-type="doi">10.1016/j.cpcardiol.2023.101869</pub-id><pub-id pub-id-type="pmid">37302648</pub-id><pub-id pub-id-type="pmcid">PMC10251728</pub-id></element-citation></ref><ref id="B60-viruses-17-00753"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Bari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mondi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pinnetti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mazzotta</surname><given-names>V.</given-names></name><name name-style="western"><surname>Carletti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Matusali</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vincenti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gagliardini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Santoro</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fontana</surname><given-names>C.</given-names></name><etal/></person-group><article-title>A Case of Severe Mpox Complicated with Streptococcus Pyogenes Sepsis in a Patient with HIV Infection</article-title><source>Pathogens</source><year>2023</year><volume>12</volume><elocation-id>1073</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens12091073</pub-id><pub-id pub-id-type="pmid">37764881</pub-id><pub-id pub-id-type="pmcid">PMC10534985</pub-id></element-citation></ref><ref id="B61-viruses-17-00753"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alhazzani</surname><given-names>W.</given-names></name><name name-style="western"><surname>Antonelli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Coopersmith</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>French</surname><given-names>C.</given-names></name><name name-style="western"><surname>Machado</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Mcintyre</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ostermann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Prescott</surname><given-names>H.C.</given-names></name><etal/></person-group><article-title>Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021</article-title><source>Crit. Care Med.</source><year>2021</year><volume>49</volume><fpage>e1063</fpage><lpage>e1143</lpage><pub-id pub-id-type="doi">10.1097/CCM.0000000000005337</pub-id><pub-id pub-id-type="pmid">34605781</pub-id></element-citation></ref><ref id="B62-viruses-17-00753"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rayati Damavandi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Semnani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hassanpour</surname><given-names>K.</given-names></name></person-group><article-title>A Review of Monkeypox Ocular Manifestations and Complications: Insights for the 2022 Outbreak</article-title><source>Ophthalmol. Ther.</source><year>2023</year><volume>12</volume><fpage>55</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1007/s40123-022-00626-4</pub-id><pub-id pub-id-type="pmid">36512187</pub-id><pub-id pub-id-type="pmcid">PMC9834445</pub-id></element-citation></ref><ref id="B63-viruses-17-00753"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carvalho</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Medeiros</surname><given-names>M.</given-names></name><name name-style="western"><surname>Veloso</surname><given-names>V.G.</given-names></name><name name-style="western"><surname>Biancardi</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Curi</surname><given-names>A.L.L.</given-names></name></person-group><article-title>Monkeypox Infection Causing Conjunctival Vesicles and Anterior Uveitis</article-title><source>Ocul. Immunol. Inflamm.</source><year>2024</year><volume>32</volume><fpage>266</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1080/09273948.2023.2174884</pub-id><pub-id pub-id-type="pmid">36800244</pub-id></element-citation></ref><ref id="B64-viruses-17-00753"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mukit</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Louie</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Cape</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Bohn</surname><given-names>S.N.</given-names></name></person-group><article-title>A Suspected Case of a Neonatal Monkeypox Infection with Ocular Involvement</article-title><source>Cureus</source><year>2023</year><volume>15</volume><fpage>e38819</fpage><pub-id pub-id-type="doi">10.7759/cureus.38819</pub-id><pub-id pub-id-type="pmid">37303431</pub-id><pub-id pub-id-type="pmcid">PMC10251443</pub-id></element-citation></ref><ref id="B65-viruses-17-00753"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Mentreddy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schallhorn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aung</surname><given-names>S.</given-names></name><name name-style="western"><surname>Doernberg</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Babik</surname><given-names>J.</given-names></name><name name-style="western"><surname>Miles</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lydon</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Isolated Ocular Mpox without Skin Lesions, United States</article-title><source>Emerg. Infect. Dis.</source><year>2023</year><volume>29</volume><fpage>1285</fpage><lpage>1288</lpage><pub-id pub-id-type="doi">10.3201/eid2906.230032</pub-id><pub-id pub-id-type="pmid">37130504</pub-id><pub-id pub-id-type="pmcid">PMC10202873</pub-id></element-citation></ref><ref id="B66-viruses-17-00753"><label>66.</label><element-citation publication-type="gov"><article-title>CDC Interim Clinical Considerations for Management of Ocular Mpox</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/mpox/hcp/clinical-care/ocular-infection.html" ext-link-type="uri">https://www.cdc.gov/mpox/hcp/clinical-care/ocular-infection.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-25">(accessed on 25 February 2025)</date-in-citation></element-citation></ref><ref id="B67-viruses-17-00753"><label>67.</label><element-citation publication-type="webpage"><article-title>Clinical Management and Infection Prevention and Control for Monkeypox: Interim Rapid Response Guidance, 10 June 2022</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications/i/item/WHO-MPX-Clinical-and-IPC-2022.1" ext-link-type="uri">https://www.who.int/publications/i/item/WHO-MPX-Clinical-and-IPC-2022.1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-25">(accessed on 25 February 2025)</date-in-citation></element-citation></ref><ref id="B68-viruses-17-00753"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maredia</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sartori-Valinotti</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Ranganath</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tosh</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>O&#8217;Horo</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>A.S.</given-names></name></person-group><article-title>Supportive Care Management Recommendations for Mucocutaneous Manifestations of Monkeypox Infection</article-title><source>Mayo Clin. Proc.</source><year>2023</year><volume>98</volume><fpage>828</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1016/j.mayocp.2023.01.019</pub-id><pub-id pub-id-type="pmid">37125977</pub-id><pub-id pub-id-type="pmcid">PMC10148669</pub-id></element-citation></ref><ref id="B69-viruses-17-00753"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdulkarim</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ticknor</surname><given-names>I.L.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Mohammed</surname><given-names>T.O.</given-names></name><name name-style="western"><surname>Rees</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Baghchechi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Streams</surname><given-names>B.N.</given-names></name></person-group><article-title>Cutaneous Findings of Fulminant Monkeypox in a Patient with HIV/AIDS</article-title><source>JAAD Case Rep.</source><year>2023</year><volume>38</volume><fpage>32</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.jdcr.2023.05.027</pub-id><pub-id pub-id-type="pmid">37362629</pub-id><pub-id pub-id-type="pmcid">PMC10275391</pub-id></element-citation></ref><ref id="B70-viruses-17-00753"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calin</surname><given-names>R.</given-names></name><name name-style="western"><surname>P&#233;rillaud-Dubois</surname><given-names>C.</given-names></name><name name-style="western"><surname>Marot</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kerrou</surname><given-names>K.</given-names></name><name name-style="western"><surname>Peytavin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bachir</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kirch</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Lassel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fallet</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gozlan</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Mpox Hepatic and Pulmonary Lesions in HIV/Hepatitis B Virus Co-Infected Patient, France</article-title><source>Emerg. Infect. Dis.</source><year>2024</year><volume>30</volume><fpage>2445</fpage><lpage>2447</lpage><pub-id pub-id-type="doi">10.3201/eid3011.241331</pub-id><pub-id pub-id-type="pmid">39447209</pub-id><pub-id pub-id-type="pmcid">PMC11521180</pub-id></element-citation></ref><ref id="B71-viruses-17-00753"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warner</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Shishido</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fulco</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Sastry</surname><given-names>S.</given-names></name></person-group><article-title>Immune Reconstitution Inflammatory Syndrome Due to Monkeypox in Two Patients with AIDS</article-title><source>AIDS</source><year>2023</year><volume>37</volume><fpage>1187</fpage><lpage>1188</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000003541</pub-id><pub-id pub-id-type="pmid">37139659</pub-id></element-citation></ref><ref id="B72-viruses-17-00753"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>A.K.</given-names></name></person-group><article-title>Interim Clinical Treatment Considerations for Severe Manifestations of Mpox&#8212;United States, February 2023</article-title><source>MMWR Morb. Mortal. Wkly. Rep.</source><year>2023</year><volume>72</volume><fpage>232</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7209a4</pub-id><pub-id pub-id-type="pmid">36862595</pub-id><pub-id pub-id-type="pmcid">PMC9997665</pub-id></element-citation></ref><ref id="B73-viruses-17-00753"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ragab</surname><given-names>D.</given-names></name><name name-style="western"><surname>Salah Eldin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Taeimah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khattab</surname><given-names>R.</given-names></name><name name-style="western"><surname>Salem</surname><given-names>R.</given-names></name></person-group><article-title>The COVID-19 Cytokine Storm; What We Know So Far</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><elocation-id>1446</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.01446</pub-id><pub-id pub-id-type="pmid">32612617</pub-id><pub-id pub-id-type="pmcid">PMC7308649</pub-id></element-citation></ref><ref id="B74-viruses-17-00753"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lansiaux</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>N.</given-names></name><name name-style="western"><surname>Laivacuma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reinis</surname><given-names>A.</given-names></name></person-group><article-title>The Virology of Human Monkeypox Virus (hMPXV): A Brief Overview</article-title><source>Virus Res.</source><year>2022</year><volume>322</volume><fpage>198932</fpage><pub-id pub-id-type="doi">10.1016/j.virusres.2022.198932</pub-id><pub-id pub-id-type="pmid">36165924</pub-id><pub-id pub-id-type="pmcid">PMC9534104</pub-id></element-citation></ref><ref id="B75-viruses-17-00753"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alkhalil</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hammamieh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hardick</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ichou</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Jett</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>S.</given-names></name></person-group><article-title>Gene Expression Profiling of Monkeypox Virus-Infected Cells Reveals Novel Interfaces for Host-Virus Interactions</article-title><source>Virol. J.</source><year>2010</year><volume>7</volume><fpage>173</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-7-173</pub-id><pub-id pub-id-type="pmid">20667104</pub-id><pub-id pub-id-type="pmcid">PMC2920256</pub-id></element-citation></ref><ref id="B76-viruses-17-00753"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petersen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kantele</surname><given-names>A.</given-names></name><name name-style="western"><surname>Koopmans</surname><given-names>M.</given-names></name><name name-style="western"><surname>Asogun</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yinka-Ogunleye</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ihekweazu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zumla</surname><given-names>A.</given-names></name></person-group><article-title>Human Monkeypox: Epidemiologic and Clinical Characteristics, Diagnosis, and Prevention</article-title><source>Infect. Dis. Clin. N. Am.</source><year>2019</year><volume>33</volume><fpage>1027</fpage><lpage>1043</lpage><pub-id pub-id-type="doi">10.1016/j.idc.2019.03.001</pub-id><pub-id pub-id-type="pmcid">PMC9533922</pub-id><pub-id pub-id-type="pmid">30981594</pub-id></element-citation></ref><ref id="B77-viruses-17-00753"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q.-Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.-X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.-H.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>L.-L.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name></person-group><article-title>The Land-Scape of Immune Response to Monkeypox Virus</article-title><source>eBioMedicine</source><year>2022</year><volume>87</volume><elocation-id>104424</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2022.104424</pub-id><pub-id pub-id-type="pmid">36584594</pub-id><pub-id pub-id-type="pmcid">PMC9797195</pub-id></element-citation></ref><ref id="B78-viruses-17-00753"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villarino</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Kanno</surname><given-names>Y.</given-names></name><name name-style="western"><surname>O&#8217;Shea</surname><given-names>J.J.</given-names></name></person-group><article-title>Mechanisms and Consequences of Jak-STAT Signaling in the Immune System</article-title><source>Nat. Immunol.</source><year>2017</year><volume>18</volume><fpage>374</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1038/ni.3691</pub-id><pub-id pub-id-type="pmid">28323260</pub-id><pub-id pub-id-type="pmcid">PMC11565648</pub-id></element-citation></ref><ref id="B79-viruses-17-00753"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fern&#225;ndez de Marco</surname><given-names>M.</given-names></name></person-group><article-title>del M.; Alejo, A.; Hudson, P.; Damon, I.K.; Alcami, A. The Highly Virulent Variola and Monkeypox Viruses Express Secreted Inhibitors of Type I Interferon</article-title><source>FASEB J.</source><year>2010</year><volume>24</volume><fpage>1479</fpage><lpage>1488</lpage><pub-id pub-id-type="doi">10.1096/fj.09-144733</pub-id><pub-id pub-id-type="pmid">20019241</pub-id><pub-id pub-id-type="pmcid">PMC2857867</pub-id></element-citation></ref><ref id="B80-viruses-17-00753"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esteban</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Nuara</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Buller</surname><given-names>R.M.L.</given-names></name></person-group><article-title>Interleukin-18 and Glycosaminoglycan Binding by a Protein Encoded by Variola Virus</article-title><source>J. Gen. Virol.</source><year>2004</year><volume>85</volume><fpage>1291</fpage><lpage>1299</lpage><pub-id pub-id-type="doi">10.1099/vir.0.79902-0</pub-id><pub-id pub-id-type="pmid">15105546</pub-id></element-citation></ref><ref id="B81-viruses-17-00753"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hudson</surname><given-names>P.N.</given-names></name><name name-style="western"><surname>Self</surname><given-names>J.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>S.</given-names></name><name name-style="western"><surname>Braden</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Girgis</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Emerson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sammons</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Isaacs</surname><given-names>S.N.</given-names></name><etal/></person-group><article-title>Elucidating the Role of the Complement Control Protein in Monkeypox Pathogenicity</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e35086</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0035086</pub-id><pub-id pub-id-type="pmid">22496894</pub-id><pub-id pub-id-type="pmcid">PMC3322148</pub-id></element-citation></ref><ref id="B82-viruses-17-00753"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Pace</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bruzzone</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ricucci</surname><given-names>V.</given-names></name><name name-style="western"><surname>Domnich</surname><given-names>A.</given-names></name><name name-style="western"><surname>Guarona</surname><given-names>G.</given-names></name><name name-style="western"><surname>Garzillo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Qosja</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ciccarese</surname><given-names>G.</given-names></name><name name-style="western"><surname>Di Biagio</surname><given-names>A.</given-names></name><name name-style="western"><surname>Orsi</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Molecular Diagnosis of Human Monkeypox Virus during 2022&#8211;23 Outbreak: Preliminary Evaluation of Novel Real-Time Qualitative PCR Assays</article-title><source>Microorganisms</source><year>2024</year><volume>12</volume><elocation-id>664</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms12040664</pub-id><pub-id pub-id-type="pmid">38674608</pub-id><pub-id pub-id-type="pmcid">PMC11052509</pub-id></element-citation></ref><ref id="B83-viruses-17-00753"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>K.-A.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Nam</surname><given-names>J.-H.</given-names></name></person-group><article-title>Diagnosis of Viral Infection Using Real-Time Polymerase Chain Reaction</article-title><source>J. Bacteriol. Virol.</source><year>2018</year><volume>48</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.4167/jbv.2018.48.1.1</pub-id></element-citation></ref><ref id="B84-viruses-17-00753"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dronina</surname><given-names>J.</given-names></name><name name-style="western"><surname>Samukaite-Bubniene</surname><given-names>U.</given-names></name><name name-style="western"><surname>Ramanavicius</surname><given-names>A.</given-names></name></person-group><article-title>Advances and Insights in the Diagnosis of Viral Infections</article-title><source>J. Nanobiotechnology</source><year>2021</year><volume>19</volume><elocation-id>348</elocation-id><pub-id pub-id-type="doi">10.1186/s12951-021-01081-2</pub-id><pub-id pub-id-type="pmid">34717656</pub-id><pub-id pub-id-type="pmcid">PMC8556785</pub-id></element-citation></ref><ref id="B85-viruses-17-00753"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Altindis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Puca</surname><given-names>E.</given-names></name><name name-style="western"><surname>Shapo</surname><given-names>L.</given-names></name></person-group><article-title>Diagnosis of Monkeypox Virus&#8212;An Overview</article-title><source>Travel. Med. Infect. Dis.</source><year>2022</year><volume>50</volume><fpage>102459</fpage><pub-id pub-id-type="doi">10.1016/j.tmaid.2022.102459</pub-id><pub-id pub-id-type="pmid">36109000</pub-id><pub-id pub-id-type="pmcid">PMC9534096</pub-id></element-citation></ref><ref id="B86-viruses-17-00753"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sui</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name></person-group><article-title>CRISPR-Cas12a-Based Detection of Monkeypox Virus</article-title><source>J. Infect.</source><year>2022</year><volume>85</volume><fpage>702</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2022.08.043</pub-id><pub-id pub-id-type="pmcid">PMC9628776</pub-id><pub-id pub-id-type="pmid">36084670</pub-id></element-citation></ref><ref id="B87-viruses-17-00753"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grant</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Nalca</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zoll</surname><given-names>S.</given-names></name><name name-style="western"><surname>Blyn</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Eshoo</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Matthews</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sampath</surname><given-names>R.</given-names></name><name name-style="western"><surname>Whitehouse</surname><given-names>C.A.</given-names></name></person-group><article-title>Application of the Ibis-T5000 Pan-Orthopoxvirus Assay to Quantitatively Detect Monkeypox Viral Loads in Clinical Specimens from Macaques Experimentally Infected with Aerosolized Monkeypox Virus</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2010</year><volume>82</volume><fpage>318</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.2010.09-0361</pub-id><pub-id pub-id-type="pmid">20134011</pub-id><pub-id pub-id-type="pmcid">PMC2813175</pub-id></element-citation></ref><ref id="B88-viruses-17-00753"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iizuka</surname><given-names>I.</given-names></name><name name-style="western"><surname>Saijo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shiota</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ami</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Suzaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nagata</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sakai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fukushi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mizutani</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Loop-Mediated Isothermal Amplification-Based Diagnostic Assay for Monkeypox Virus Infections</article-title><source>J. Med. Virol.</source><year>2009</year><volume>81</volume><fpage>1102</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1002/jmv.21494</pub-id><pub-id pub-id-type="pmid">19382264</pub-id></element-citation></ref><ref id="B89-viruses-17-00753"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bat&#233;jat</surname><given-names>C.</given-names></name><name name-style="western"><surname>Grassin</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Feher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hoinard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vanhomwegen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Manuguerra</surname><given-names>J.-C.</given-names></name><name name-style="western"><surname>Leclercq</surname><given-names>I.</given-names></name></person-group><article-title>Heat Inactivation of Monkeypox Virus</article-title><source>J. Biosaf. Biosecurity</source><year>2022</year><volume>4</volume><fpage>121</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.jobb.2022.08.001</pub-id><pub-id pub-id-type="pmcid">PMC9534137</pub-id><pub-id pub-id-type="pmid">36245694</pub-id></element-citation></ref><ref id="B90-viruses-17-00753"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rizk</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Lippi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Henry</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Forthal</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Rizk</surname><given-names>Y.</given-names></name></person-group><article-title>Prevention and Treatment of Monkeypox</article-title><source>Drugs</source><year>2022</year><volume>82</volume><fpage>957</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1007/s40265-022-01742-y</pub-id><pub-id pub-id-type="pmid">35763248</pub-id><pub-id pub-id-type="pmcid">PMC9244487</pub-id></element-citation></ref><ref id="B91-viruses-17-00753"><label>91.</label><element-citation publication-type="gov"><article-title>Commissioner, O. of the Mpox. <italic toggle="yes">FDA</italic></article-title><year>2025</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/vaccines-blood-biologics/jynneos" ext-link-type="uri">https://www.fda.gov/vaccines-blood-biologics/jynneos</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-05-20">(accessed on 20 May 2025)</date-in-citation></element-citation></ref><ref id="B92-viruses-17-00753"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deputy</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Deckert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chard</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Sandberg</surname><given-names>N.</given-names></name><name name-style="western"><surname>Moulia</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Barkley</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dalton</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Sweet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cohn</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Little</surname><given-names>D.R.</given-names></name><etal/></person-group><article-title>Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United States</article-title><source>N. Engl. J. Med.</source><year>2023</year><volume>388</volume><fpage>2434</fpage><lpage>2443</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2215201</pub-id><pub-id pub-id-type="pmid">37199451</pub-id><pub-id pub-id-type="pmcid">PMC10962869</pub-id></element-citation></ref><ref id="B93-viruses-17-00753"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huber</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>S.</given-names></name></person-group><article-title>Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study&#8212;United States, August 19, 2022&#8211;March 31, 2023</article-title><source>Ann. Emerg. Med.</source><year>2023</year><volume>82</volume><fpage>520</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1016/j.annemergmed.2023.08.376</pub-id><pub-id pub-id-type="pmcid">PMC10205167</pub-id><pub-id pub-id-type="pmid">37200229</pub-id></element-citation></ref><ref id="B94-viruses-17-00753"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pischel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Martini</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cacesse</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tracy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kharbanda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>N.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Grimshaw</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Malik</surname><given-names>A.A.</given-names></name><etal/></person-group><article-title>Vaccine Effectiveness of 3rd Generation Mpox Vaccines against Mpox and Disease Severity: A Systematic Review and Meta-Analysis</article-title><source>Vaccine</source><year>2024</year><volume>42</volume><fpage>126053</fpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2024.06.021</pub-id><pub-id pub-id-type="pmid">38906763</pub-id></element-citation></ref><ref id="B95-viruses-17-00753"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan-Tack</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S.-Y.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>L.</given-names></name><name name-style="western"><surname>O&#8217;Rear</surname><given-names>J.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>S.</given-names></name><name name-style="western"><surname>McMillan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ghantous</surname><given-names>H.</given-names></name><name name-style="western"><surname>Birnkrant</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sherwat</surname><given-names>A.I.</given-names></name></person-group><article-title>Assessing a Drug for an Eradicated Human Disease: US Food and Drug Administration Review of Tecovirimat for the Treatment of Smallpox</article-title><source>Lancet Infect. Dis.</source><year>2019</year><volume>19</volume><fpage>e221</fpage><lpage>e224</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30788-6</pub-id><pub-id pub-id-type="pmid">30853252</pub-id></element-citation></ref><ref id="B96-viruses-17-00753"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sherwat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Birnkrant</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>P.</given-names></name></person-group><article-title>Tecovirimat and the Treatment of Monkeypox&#8212;Past, Present, and Future Considerations</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>387</volume><fpage>579</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1056/NEJMp2210125</pub-id><pub-id pub-id-type="pmid">35921403</pub-id></element-citation></ref><ref id="B97-viruses-17-00753"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vernuccio</surname><given-names>R.</given-names></name><name name-style="western"><surname>Le&#243;n</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Poojari</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Buchrieser</surname><given-names>J.</given-names></name><name name-style="western"><surname>Selverian</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jaleta</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Meola</surname><given-names>A.</given-names></name><name name-style="western"><surname>Guivel-Benhassine</surname><given-names>F.</given-names></name><name name-style="western"><surname>Porrot</surname><given-names>F.</given-names></name><name name-style="western"><surname>Haouz</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Mechanisms of tecovirimat antiviral activity and poxvirus resistance</article-title><source>Res. Sq.</source><year>2024</year><comment><italic toggle="yes">preprint</italic></comment><pub-id pub-id-type="doi">10.21203/rs.3.rs-5002222/v1</pub-id><pub-id pub-id-type="pmcid">PMC11879855</pub-id><pub-id pub-id-type="pmid">39939832</pub-id></element-citation></ref><ref id="B98-viruses-17-00753"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Braddick</surname><given-names>M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>K.P.</given-names></name></person-group><article-title>Therapeutic Agents for the Treatment of Human Mpox</article-title><source>Curr. Opin. Infect. Dis.</source><year>2024</year><volume>37</volume><fpage>518</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1097/QCO.0000000000001069</pub-id><pub-id pub-id-type="pmid">39382085</pub-id></element-citation></ref><ref id="B99-viruses-17-00753"><label>99.</label><element-citation publication-type="gov"><article-title>The Antiviral Tecovirimat Is Safe but Did Not Improve Clade I Mpox Resolution in Democratic Republic of the Congo</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nih.gov/news-events/news-releases/antiviral-tecovirimat-safe-did-not-improve-clade-i-mpox-resolution-democratic-republic-congo" ext-link-type="uri">https://www.nih.gov/news-events/news-releases/antiviral-tecovirimat-safe-did-not-improve-clade-i-mpox-resolution-democratic-republic-congo</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-04-12">(accessed on 12 April 2025)</date-in-citation></element-citation></ref><ref id="B100-viruses-17-00753"><label>100.</label><element-citation publication-type="webpage"><article-title>SIGA Technologies, Inc.&#8212;Interim Results from STOMP Study of SIGA&#8217;s Tecovirimat in Treatment of Mpox Announced</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://investor.siga.com/investors/news/news-details/2024/Interim-Results-from-STOMP-Study-of-SIGAs-Tecovirimat-in-Treatment-of-Mpox-Announced/default.aspx" ext-link-type="uri">https://investor.siga.com/investors/news/news-details/2024/Interim-Results-from-STOMP-Study-of-SIGAs-Tecovirimat-in-Treatment-of-Mpox-Announced/default.aspx</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-04-12">(accessed on 12 April 2025)</date-in-citation></element-citation></ref><ref id="B101-viruses-17-00753"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desai</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>G.R.</given-names><suffix>III</suffix></name><name name-style="western"><surname>Neumeister</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Arutyunova</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Trigg</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>S.H.</given-names></name></person-group><article-title>Compassionate Use of Tecovirimat for the Treatment of Monkeypox Infection</article-title><source>JAMA</source><year>2022</year><volume>328</volume><fpage>1348</fpage><lpage>1350</lpage><pub-id pub-id-type="doi">10.1001/jama.2022.15336</pub-id><pub-id pub-id-type="pmid">35994281</pub-id><pub-id pub-id-type="pmcid">PMC9396467</pub-id></element-citation></ref><ref id="B102-viruses-17-00753"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jordan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Leeds</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Tyavanagimatt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hruby</surname><given-names>D.E.</given-names></name></person-group><article-title>Development of ST-246<sup>&#174;</sup> for Treatment of Poxvirus Infections</article-title><source>Viruses</source><year>2010</year><volume>2</volume><fpage>2409</fpage><lpage>2435</lpage><pub-id pub-id-type="doi">10.3390/v2112409</pub-id><pub-id pub-id-type="pmid">21994624</pub-id><pub-id pub-id-type="pmcid">PMC3185582</pub-id></element-citation></ref><ref id="B103-viruses-17-00753"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frenois-Veyrat</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gallardo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gorg&#233;</surname><given-names>O.</given-names></name><name name-style="western"><surname>Marcheteau</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ferraris</surname><given-names>O.</given-names></name><name name-style="western"><surname>Baidaliuk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Favier</surname><given-names>A.-L.</given-names></name><name name-style="western"><surname>Enfroy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Holy</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lourenco</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Tecovirimat Is Effective against Human Monkeypox Virus in Vitro at Nanomolar Concentrations</article-title><source>Nat. Microbiol.</source><year>2022</year><volume>7</volume><fpage>1951</fpage><lpage>1955</lpage><pub-id pub-id-type="doi">10.1038/s41564-022-01269-8</pub-id><pub-id pub-id-type="pmid">36344621</pub-id></element-citation></ref><ref id="B104-viruses-17-00753"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warner</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Klassen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sloan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Deschambault</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Soule</surname><given-names>G.</given-names></name><name name-style="western"><surname>Banadyga</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Strong</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Kobasa</surname><given-names>D.</given-names></name><name name-style="western"><surname>Safronetz</surname><given-names>D.</given-names></name></person-group><article-title>In Vitro and in Vivo Efficacy of Tecovirimat against a Recently Emerged 2022 Monkeypox Virus Isolate</article-title><source>Sci. Transl. Med.</source><year>2022</year><volume>14</volume><fpage>eade7646</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.ade7646</pub-id><pub-id pub-id-type="pmid">36318038</pub-id></element-citation></ref><ref id="B105-viruses-17-00753"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Postal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guivel-Benhassine</surname><given-names>F.</given-names></name><name name-style="western"><surname>Porrot</surname><given-names>F.</given-names></name><name name-style="western"><surname>Grassin</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Crook</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Vernuccio</surname><given-names>R.</given-names></name><name name-style="western"><surname>Caro</surname><given-names>V.</given-names></name><name name-style="western"><surname>Vanhomwegen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guardado-Calvo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Simon-Lori&#232;re</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Antiviral Activity of Tecovirimat against Monkeypox Virus Clades 1a, 1b, 2a, and 2b</article-title><source>Lancet Infect. Dis.</source><year>2025</year><volume>25</volume><fpage>e126</fpage><lpage>e127</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(25)00014-3</pub-id><pub-id pub-id-type="pmid">39864448</pub-id></element-citation></ref><ref id="B106-viruses-17-00753"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delaune</surname><given-names>D.</given-names></name><name name-style="western"><surname>Iseni</surname><given-names>F.</given-names></name></person-group><article-title>Drug Development against Smallpox: Present and Future</article-title><source>Antimicrob. Agents Chemother.</source><year>2020</year><volume>64</volume><fpage>e01683-19</fpage><pub-id pub-id-type="doi">10.1128/AAC.01683-19</pub-id><pub-id pub-id-type="pmid">31932370</pub-id><pub-id pub-id-type="pmcid">PMC7179270</pub-id></element-citation></ref><ref id="B107-viruses-17-00753"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magee</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Aldern</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Hostetler</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>D.H.</given-names></name></person-group><article-title>Cidofovir and (S)-9-[3-Hydroxy-(2-Phosphonomethoxy)Propyl]Adenine Are Highly Effective Inhibitors of Vaccinia Virus DNA Polymerase When Incorporated into the Template Strand</article-title><source>Antimicrob. Agents Chemother.</source><year>2008</year><volume>52</volume><fpage>586</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1128/AAC.01172-07</pub-id><pub-id pub-id-type="pmid">18056278</pub-id><pub-id pub-id-type="pmcid">PMC2224733</pub-id></element-citation></ref><ref id="B108-viruses-17-00753"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magee</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Hostetler</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>D.H.</given-names></name></person-group><article-title>Mechanism of Inhibition of Vaccinia Virus DNA Polymerase by Cidofovir Diphosphate</article-title><source>Antimicrob. Agents Chemother.</source><year>2005</year><volume>49</volume><fpage>3153</fpage><lpage>3162</lpage><pub-id pub-id-type="doi">10.1128/AAC.49.8.3153-3162.2005</pub-id><pub-id pub-id-type="pmid">16048917</pub-id><pub-id pub-id-type="pmcid">PMC1196213</pub-id></element-citation></ref><ref id="B109-viruses-17-00753"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harikumar</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>B.B.</given-names></name></person-group><article-title>Resveratrol: A Multitargeted Agent for Age-Associated Chronic Diseases</article-title><source>Cell Cycle</source><year>2008</year><volume>7</volume><fpage>1020</fpage><lpage>1035</lpage><pub-id pub-id-type="doi">10.4161/cc.7.8.5740</pub-id><pub-id pub-id-type="pmid">18414053</pub-id></element-citation></ref><ref id="B110-viruses-17-00753"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koushki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Amiri-Dashatan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ahmadi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Abbaszadeh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rezaei-Tavirani</surname><given-names>M.</given-names></name></person-group><article-title>Resveratrol: A Miraculous Natural Compound for Diseases Treatment</article-title><source>Food Sci. Nutr.</source><year>2018</year><volume>6</volume><fpage>2473</fpage><lpage>2490</lpage><pub-id pub-id-type="doi">10.1002/fsn3.855</pub-id><pub-id pub-id-type="pmid">30510749</pub-id><pub-id pub-id-type="pmcid">PMC6261232</pub-id></element-citation></ref><ref id="B111-viruses-17-00753"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palamara</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Nencioni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Aquilano</surname><given-names>K.</given-names></name><name name-style="western"><surname>De Chiara</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cozzolino</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ciriolo</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Garaci</surname><given-names>E.</given-names></name></person-group><article-title>Inhibition of Influenza A Virus Replication by Resveratrol</article-title><source>J. Infect. Dis.</source><year>2005</year><volume>191</volume><fpage>1719</fpage><lpage>1729</lpage><pub-id pub-id-type="doi">10.1086/429694</pub-id><pub-id pub-id-type="pmid">15838800</pub-id></element-citation></ref><ref id="B112-viruses-17-00753"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W.</given-names></name></person-group><article-title>Effects of Resveratrol on the Amelioration of Insulin Resistance in KKAy Mice</article-title><source>Can. J. Physiol. Pharmacol.</source><year>2012</year><volume>90</volume><fpage>237</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1139/y11-123</pub-id><pub-id pub-id-type="pmid">22309033</pub-id></element-citation></ref><ref id="B113-viruses-17-00753"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>R.-X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>E.</given-names></name></person-group><article-title>Inhibition of Herpes Simplex Virus Infection by Oligomeric Stilbenoids through ROS Generation</article-title><source>Antivir. Res.</source><year>2012</year><volume>95</volume><fpage>30</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2012.05.001</pub-id><pub-id pub-id-type="pmid">22584350</pub-id></element-citation></ref><ref id="B114-viruses-17-00753"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clouser</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Chauhan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bess</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>van Oploo</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dimick-Gray</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mansky</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>S.E.</given-names></name></person-group><article-title>Anti-HIV-1 Activity of Resveratrol Derivatives and Synergistic Inhibition of HIV-1 by the Combination of Resveratrol and Decitabine</article-title><source>Bioorg Med. Chem. Lett.</source><year>2012</year><volume>22</volume><fpage>6642</fpage><lpage>6646</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2012.08.108</pub-id><pub-id pub-id-type="pmid">23010273</pub-id><pub-id pub-id-type="pmcid">PMC3482103</pub-id></element-citation></ref><ref id="B115-viruses-17-00753"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saito</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hokari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hibi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Miura</surname><given-names>S.</given-names></name></person-group><article-title>An Antioxidant Resveratrol Significantly Enhanced Replication of Hepatitis C Virus</article-title><source>World J. Gastroenterol.</source><year>2010</year><volume>16</volume><fpage>184</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.3748/wjg.v16.i2.184</pub-id><pub-id pub-id-type="pmid">20066737</pub-id><pub-id pub-id-type="pmcid">PMC2806556</pub-id></element-citation></ref><ref id="B116-viruses-17-00753"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galindo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hern&#225;ez</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bern&#225;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fenoll</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cenis</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Escribano</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>C.</given-names></name></person-group><article-title>Comparative Inhibitory Activity of the Stilbenes Resveratrol and Oxyresveratrol on African Swine Fever Virus Replication</article-title><source>Antivir. Res.</source><year>2011</year><volume>91</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2011.04.013</pub-id><pub-id pub-id-type="pmid">21557969</pub-id></element-citation></ref><ref id="B117-viruses-17-00753"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Espinoza</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Takami</surname><given-names>A.</given-names></name><name name-style="western"><surname>Trung</surname><given-names>L.Q.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nakao</surname><given-names>S.</given-names></name></person-group><article-title>Resveratrol Prevents EBV Transformation and Inhibits the Outgrowth of EBV-Immortalized Human B Cells</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e51306</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0051306</pub-id><pub-id pub-id-type="pmid">23251493</pub-id><pub-id pub-id-type="pmcid">PMC3519585</pub-id></element-citation></ref><ref id="B118-viruses-17-00753"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>X.-H.</given-names></name><name name-style="western"><surname>Zang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>E.</given-names></name></person-group><article-title>Resveratrol Inhibits Respiratory Syncytial Virus-Induced IL-6 Production, Decreases Viral Replication, and Downregulates TRIF Expression in Airway Epithelial Cells</article-title><source>Inflammation</source><year>2012</year><volume>35</volume><fpage>1392</fpage><lpage>1401</lpage><pub-id pub-id-type="doi">10.1007/s10753-012-9452-7</pub-id><pub-id pub-id-type="pmid">22391746</pub-id></element-citation></ref><ref id="B119-viruses-17-00753"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>R.</given-names></name><name name-style="western"><surname>Song</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Inhibitory Effect of Resveratrol against Duck Enteritis Virus in Vitro</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e65213</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0065213</pub-id><pub-id pub-id-type="pmid">23776451</pub-id><pub-id pub-id-type="pmcid">PMC3679110</pub-id></element-citation></ref><ref id="B120-viruses-17-00753"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abba</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hassim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hamzah</surname><given-names>H.</given-names></name><name name-style="western"><surname>Noordin</surname><given-names>M.M.</given-names></name></person-group><article-title>Antiviral Activity of Resveratrol against Human and Animal Viruses</article-title><source>Adv. Virol.</source><year>2015</year><volume>2015</volume><fpage>184241</fpage><pub-id pub-id-type="doi">10.1155/2015/184241</pub-id><pub-id pub-id-type="pmid">26693226</pub-id><pub-id pub-id-type="pmcid">PMC4676993</pub-id></element-citation></ref><ref id="B121-viruses-17-00753"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Realegeno</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pant</surname><given-names>A.</given-names></name><name name-style="western"><surname>Satheshkumar</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name></person-group><article-title>Suppression of Poxvirus Replication by Resveratrol</article-title><source>Front. Microbiol.</source><year>2017</year><volume>8</volume><elocation-id>2196</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2017.02196</pub-id><pub-id pub-id-type="pmid">29204136</pub-id><pub-id pub-id-type="pmcid">PMC5698801</pub-id></element-citation></ref><ref id="B122-viruses-17-00753"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Shahid</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tamanna</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Marma</surname><given-names>H.</given-names></name></person-group><article-title>Therapeutic Promises of Plant Metabolites against Monkeypox Virus: An in Silico Study</article-title><source>Adv. Virol.</source><year>2023</year><volume>2023</volume><fpage>9919776</fpage><pub-id pub-id-type="doi">10.1155/2023/9919776</pub-id><pub-id pub-id-type="pmid">37693295</pub-id><pub-id pub-id-type="pmcid">PMC10492655</pub-id></element-citation></ref><ref id="B123-viruses-17-00753"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bajrai</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Alharbi</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>El-Day</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Bafaraj</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Dwivedi</surname><given-names>V.D.</given-names></name><name name-style="western"><surname>Azhar</surname><given-names>E.I.</given-names></name></person-group><article-title>Identification of Antiviral Compounds against Monkeypox Virus Profilin-like Protein A42R from Plantago Lanceolata</article-title><source>Molecules</source><year>2022</year><volume>27</volume><elocation-id>7718</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27227718</pub-id><pub-id pub-id-type="pmid">36431817</pub-id><pub-id pub-id-type="pmcid">PMC9697570</pub-id></element-citation></ref><ref id="B124-viruses-17-00753"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Vliet</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Villa</surname><given-names>N.Y.</given-names></name><name name-style="western"><surname>Werden</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>McFadden</surname><given-names>G.</given-names></name></person-group><article-title>Poxvirus Proteomics and Virus-Host Protein Interactions</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2009</year><volume>73</volume><fpage>730</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1128/MMBR.00026-09</pub-id><pub-id pub-id-type="pmid">19946139</pub-id><pub-id pub-id-type="pmcid">PMC2786582</pub-id></element-citation></ref><ref id="B125-viruses-17-00753"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Witke</surname><given-names>W.</given-names></name></person-group><article-title>The Role of Profilin Complexes in Cell Motility and Other Cellular Processes</article-title><source>Trends Cell Biol.</source><year>2004</year><volume>14</volume><fpage>461</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2004.07.003</pub-id><pub-id pub-id-type="pmid">15308213</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-17-00753-f001" orientation="portrait"><label>Figure 1</label><caption><p>The schematic representation of intracellular mature virus releasing in a host cell, the cisternae of rough endoplasmic reticulum (rER) assemble and form mini nuclei in a host cell, and a large number of mitochondria are found near the mini nuclei. The replication of viral DNA occurs and forms m-RNA, which further forms viral protein, which is covered with an envelope and forms an intracellular mature virus.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="viruses-17-00753-g001.jpg"/></fig><fig position="float" id="viruses-17-00753-f002" orientation="portrait"><label>Figure 2</label><caption><p>(<bold>a</bold>) Shows the geographical distribution of Mpox in countries affected in Africa. Figure credit source: WHO. (<bold>b</bold>) Trends in confirmed Mpox cases in Africa (data as of 6 April 2025). Updated data from 1 January 2024 to 6 April 2025. The data shown here include laboratory-confirmed cases only. In the Democratic Republic of the Congo, a small number of cases are not represented on the epidemic curves due to missing data. Brackets at the end of the curve indicate potential reporting delays in recent weeks of data. Figure and data source: WHO.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="viruses-17-00753-g002.jpg"/></fig><fig position="float" id="viruses-17-00753-f003" orientation="portrait"><label>Figure 3</label><caption><p>A schematic diagram of the Mpox virus and its entry route in humans was created by biorender.com. (<bold>A</bold>) Shows the structure of the Mpox virus. (<bold>B</bold>) Shows virus entry in humans through different routes. (<bold>C</bold>) Shows the entry of the Mpox virus through the skin route. (<bold>D</bold>) Shows the entry of the Mpox virus through respiratory epithelium in humans.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="viruses-17-00753-g003.jpg"/></fig><fig position="float" id="viruses-17-00753-f004" orientation="portrait"><label>Figure 4</label><caption><p>The schematic diagram shows an Mpox-infected liver and testis and its evading mechanism in host cells with cytokine storm production, representing increased Th2-mediated immune response and decreased TH1-mediated immune response.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="viruses-17-00753-g004.jpg"/></fig></floats-group></article></pmc-articleset>